

## **Exhibit 1G: Intercompany transfers between Purdue and TXP Services Inc. for financial and tax services**

On January 1, 2008, Purdue entered into a tax services agreement with TXP, the service provider.

### **TAX SERVICES AGREEMENT**

This Tax Services Agreement (the "Agreement") effective as of January 1, 2008 by and between Purdue Pharma L.P., a Delaware limited partnership ("PPLP"), and TXP Services Inc., a Delaware corporation ("TXP"),

#### W I T N E S S E T H :

WHEREAS, TXP is engaged in the tax services business; and

WHEREAS, PPLP wishes to engage TXP to perform tax services in support of PPLP's business;

NOW, THEREFORE, in consideration of the premises and of the mutual agreements hereinafter contained, the parties hereto agree as follows:

1. Direction of Services. At all times the services provided by TXP to PPLP

## **Exhibit 1G: Intercompany transfers between Purdue and TXP Services Inc. for financial and tax services**

Pursuant to this agreement, Purdue agreed to pay costs and expenses incurred by TXP plus a service charge of 10%.

### **4. Invoices and Payment.**

(a) Within thirty (30) days of the last day of each calendar quarter ending on the last day of each March, June, September and December (each a "Calendar Quarter"), TXP shall submit to PPLP an invoice summarizing the costs and expenses incurred by TXP in providing its services hereunder during such Calendar Quarter and containing a service charge in the amount of ten percent (10%) of such costs and expenses.

## Exhibit 1G: Intercompany transfers between Purdue and TXP Services Inc. for financial and tax services

In July 2018, Purdue entered into a new services agreement with TXP on a fixed-fee basis.

**Services Agreement**  
**DCG & T&E, Finance & Accounting Services, Payroll, Taxation, Accounts Payable, Cash**  
**Management and Insurance**

PURDUE PHARMA L.P. AND TXP SERVICES INC.

THIS Services Agreement ("Services Agreement") is effective as of July 1, 2018 ("Effective Date") by and between Purdue Pharma L.P. ("Purdue") and TXP Services Inc. ("TXP").

3. Compensation: TXP's fee for services performed under this Services Agreement from July 1, 2018 through December 31, 2018 (the "2018 Fixed Fee") shall be [REDACTED]. TXP's fee for services performed under this Services Agreement in 2019 and thereafter shall comprise:
- (a) A fixed fee representing the amount payable for services provided in a given calendar year (the "Fixed Fee"). The Fixed Fee in 2019 shall be [REDACTED]. The Fixed Fee in 2020 shall be equal to the Fixed Fee for 2019 year increased by [REDACTED]. The Fixed Fee in 2021 and thereafter will be determined in the annual budget process as set forth at the end of this Section 3.

## Exhibit 1G: Intercompany transfers between Purdue and TXP Services Inc. for financial and tax services

The July 2018 services agreement was later amended on August 8, 2019 to amend, among other clauses, the fixed fee for 2019 services to be rendered.

### AMENDMENT TO SERVICES AGREEMENT

This AMENDMENT TO SERVICES AGREEMENT (this “Amendment”), dated as of August [8], 2019 (the “Effective Date”), is entered into by and between Purdue Pharma L.P., a Delaware limited partnership (“PPLP”), and TXP Services Inc., a Delaware corporation (“TXP”), and amends that certain Services Agreement DCG & T&E, Finance & Accounting Services, Payroll, Taxation, Accounts Payable, Cash Management and Insurance by and between PPLP and TXP effective as of July 1, 2018 (the “Services Agreement”). Capitalized terms used herein and not otherwise defined herein shall have the meanings given to such terms in the Services Agreement.

3. Compensation. Effective as of the Effective Date, Section 3 of the Services Agreement is hereby amended to:

- (a) delete and replace in its entirety the number “[REDACTED]” in the second sentence of subsection (a) thereof with: “[REDACTED]”;

## Exhibit 1G: Intercompany transfers between Purdue and TXP Services Inc. for financial and tax services

From January 1, 2008 to December 31, 2018, Purdue was charged \$18.6 million by TXP pursuant to the tax services agreements (costs and expenses plus service charges), including markups of \$1.4 million.<sup>1</sup> As of September 15, 2019, TXP had charged Purdue \$2.6 million for tax services under the fixed-fee arrangement, plus other amounts due under the July 2018 Services Agreement, as amended.

Year	Cost & Expenses	Markups	Total Charges for Financial & Tax Services
2008	\$ 943,966	\$ 94,397	\$ 1,038,363
2009	883,035	88,304	971,339
2010	1,705,741	170,574	1,876,315
2011	1,735,277	173,528	1,908,805
2012	1,700,502	170,050	1,870,552
2013	1,681,641	168,164	1,849,805
2014	1,148,142	114,841	1,262,983
2015	1,114,770	111,477	1,226,247
2016	1,270,694	117,502	1,388,196
2017	1,413,877	141,388	1,555,265
2018	2,418,975	83,937	2,502,912
2019	2,559,793	-	2,559,793
<b>Total</b>	<b>\$ 18,576,413</b>	<b>\$ 1,434,162</b>	<b>\$ 20,010,575</b>

<sup>1</sup>In addition, beginning in 2018 up to September 15, 2019, TXP received \$787,783 from Rhodes Tech and \$542,778 from Rhodes Pharma. TXP also paid Rhodes Tech \$2,750 between 2009 and 2010. No other payments from TXP to Rhodes entities were observed between January 1, 2008 and September 15, 2019.

## Exhibit 1G: Intercompany transfers between Purdue and TXP Services Inc. for financial and tax services

According to PPLP's accounting records in SAP, the "Purdue bank group" of companies<sup>1</sup> was charged through G/L accounts 793160 (TXP Cost Assessment) and 793170 (TXP Mark Up) for financial and tax services. The amounts for 2008 and 2017 are illustrated below.

CC Comparison w/o Commitments										
<div> <div>Variation: Cost Center</div> <div> <div>Cost Center Group</div> <ul style="list-style-type: none"> <li>2301208 FINANCE 208</li> <li>2301213 FINANCE 213</li> <li>2301219 FINANCE 219</li> <li>2301307 FINANCE 307</li> <li>2301313 FINANCE 313</li> </ul> </div> </div>										
<div> <div>Cost Center Comparison Report with Company Code</div> <div> <div>Date: 06/19/2019</div> <div>Time: 17:09:09</div> </div> </div>										
<div> <div>Current Period: 12 2008</div> <div>Plan Version: 0 Purdue Plan/Act - Version</div> <div>Cost Center / Group: *</div> <div>Company Code: 208, Company code</div> </div>										
Account	Act. Period 12	Plan Period 12	Var Period 12	Var %	Act. Per. 1-12	Plan Per. 1-12	Var. Per.1-12	Var %	200	
793160 TXP Cost Assessmt	271,559	0	(271,559)	0	943,966	0	(943,966)	0		
793170 TXP MARK UP	27,156	0	(27,156)	0	94,397	0	(94,397)	0		
* Total	298,715	0	(298,715)	0	1,038,363	0	(1,038,363)	0		

CC Comparison w/o Commitments										
<div> <div>Variation: Cost Center</div> <div> <div>Cost Center Group</div> <ul style="list-style-type: none"> <li>2301208 FINANCE 208</li> <li>2301225 FINANCE 225</li> <li>2301231 FINANCE 231</li> </ul> </div> </div>										
<div> <div>Cost Center Comparison Report with Company Code</div> <div> <div>Date: 06/19/2019</div> <div>Time: 16:55:58</div> </div> </div>										
<div> <div>Current Period: 12 2017</div> <div>Plan Version: 0 Purdue Plan/Act - Version</div> <div>Cost Center / Group: *</div> <div>Company Code: 208, Company code</div> </div>										
Account	Act. Period 12	Plan Period 12	Var Period 12	Var %	Act. Per. 1-12	Plan Per. 1-12	Var. Per.1-12	Var %	201	
793160 TXP Cost Assessmt	199,116	130,571	(68,545)	(52)	1,413,877	1,230,081	(183,796)	(15)	1	
793170 TXP MARK UP	19,912	13,058	(6,854)	(52)	141,388	123,013	(18,375)	(15)		
* Total	219,027	143,629	(75,398)	(52)	1,555,265	1,353,094	(202,171)	(15)	1	

<sup>1</sup>The Purdue bank group of companies includes SAP company codes 208, 211, 213, 219, 225, 231, 240, 241, 256, 257, 258, 307, 313, and 318.



## Exhibit 1G: Intercompany transfers between Purdue and TXP Services Inc. for financial and tax services

The methodology for allocating costs to Purdue changed in late 2018, necessitating manual journal entries to true-up the amount due from Purdue. The approved tie-out schedules detailing these manual entries is illustrated below (and on the next slide).

TXP Services, Inc. 2018 Actual									
	2300415 Treasury	2301415 Tax	2305415 Credit & Collections	2331415 Accounting Svc	2333415 Payroll	2334415 Accounts Payable	2350415 Corp. Procurement	Total	Already assessed (Through Old TXP Assessment)
	P③	P⑤	P⑥	P⑦	P⑨	P⑪	P⑬		Secondaries
PPLP and Associated Companies:									
208	\$ 239,420.84	\$ 583,292.21	\$ 33,032.87	\$ 249,930.54	\$ 167,314.88	\$ 193,757.02	\$ 82,563.96	\$ 1,549,312.31	851,100.37
211	-	2,000.00	-	-	-	141.17	-	2,141.17	-
219	-	-	-	-	79,930.13	88,831.77	6,688.14	175,450.04	-
225	-	2,000.00	-	-	-	282.34	-	2,282.34	713.69
231	-	2,000.00	-	-	2,500.00	494.10	-	4,994.10	713.69
241	-	-	-	-	-	3,246.93	-	3,246.93	-
256 Imbrium Therapeutics L.P.	-	-	-	-	2,816.19	35.29	-	2,851.48	-
257 Greenfield BioVentures LP	-	-	-	-	2,500.00	-	-	2,500.00	-
313	-	-	-	-	-	882.32	-	882.32	-
318	-	-	-	-	22,115.38	37,057.35	2,075.63	61,248.37	-
418	-	-	-	-	-	-	-	-	-
Rhodes Balancing Figure <sup>(1)</sup>	35,399.23	177,743.11	66,064.89	21,067.21	79,109.47	131,742.72	15,688.43	526,815.06	1,564,688.81
Charge to Company 208	274,830.07	767,035.32	99,097.75	270,997.75	356,286.06	456,471.01	107,016.16	2,331,724.13	(85,492.43) Credit for Tax Services - actuals less than previous assessment
307	-	-	128,168.69	-	2,500.00	34,798.62	-	165,467.31	1,479,196.38
Subtotal PPLP	274,820.07	767,035.32	227,266.44	270,997.75	358,786.06	491,269.63	107,016.16	2,497,191.43	1,644,663.68
									713.71

<sup>(1)</sup> Chargeback for Rhodes above represent fixed at the 2018 amounts agreed to by Jon Lowne and David Fogel. The "balancing figure" represents the charge to PPLP to cover the charges that would have been charged to Rhodes using the current methodologies for billing.

① 1,479,196.38

② 713.72

J/E 1,478,482.66 ②

# Exhibit 1G: Intercompany transfers between Purdue and TXP Services Inc. for financial and tax services

Examples from the 2018 cost allocation tie-out (cont.).

Tax  
2301415

		2018 Actuals	2018 LE	Favorable (Unfavorable)
603000	Salaries - Exempt	710,592.18	629,886.28	(80,705.90) (1)
604000	Payroll Taxes	50,730.32	53,327.89	2,597.57
605100	Fringe Benefit Other (BI Awards)	2,412.50	-	(2,412.50)
605110	Educational Assistance	8,325.00	5,520.00	(2,805.00)
606000	Annual Bonus	74,485.00	74,485.00	-
606030	Long Term Awards	(103,111.86)	11,443.26	114,555.12 (1)
607700	Emp Dining/Co Events	(421.54)	-	421.54
605115	Fringe Ben Adj Acct	(41,796.43)	-	41,796.43
792000	Fringe Benefits	142,083.48	142,083.48	-
605116	Fleet Adjustment Account	3,956.06	-	(3,956.06)
792010	Fleet Allocation	14,268.31	14,268.31	-
	Subtotal Compensation	861,523.02	931,014.22	69,491.20
606400	Travel Other	105.00	500.00	395.00
606420	Meals and Ent.	211.37	750.00	538.63
606510	Ext. Training Exp	2,530.20	2,600.00	69.80
606800	Office Supplies	126.73	750.00	623.27
608400	Misc Proc. Card	(29.00)	(29.00)	-
607050	Canned Software	63,163.54	100,713.58	37,550.04
607300	Dues	2,369.00	2,000.00	(369.00)
607310	Subscription - Books	314.45	350.00	35.55
608450	External Accounting	20,919.60	20,919.60	-
608640	Outside Services	(3,084.00)	12,000.00	15,084.00
650010	Other Taxes	(399.00)	(221.00)	178.00
	Subtotal Direct Costs	947,750.91	1,071,347.39	123,596.48
607510	Outside Rent	15,831.30	15,831.30	-
690600	Indirect Costs	51,417.28	105,766.04	54,348.76
	Subtotal Indirect Costs	67,248.58	121,597.34	54,348.76
690300	TXP Direct Cost	-	-	-
793160	TXP Direct Cost	(926,206.30)	(1,071,347.39)	(145,141.09)
793170	TXP Mark Up	(92,620.66)	(107,134.74)	(14,514.08)
690400	TXP Mark Up	-	-	-
690500	TXP Indirect Cost	(4,000.00)	(121,597.34)	(117,597.34)
	Subtotal TXP Revenue	(1,022,826.96)	(1,300,079.47)	(277,252.51)
	(Profit)	(7,827.47)	(107,134.74)	(99,307.27)
	Headcount	3.00	3.00	3.00

(1) Credit due to forfeiture of LTRP grant as a result of reduction of 1 FTE in 2018.  
(2) LE excluded severance.

Calculation of amount to be assessed out:

Direct Costs	947,750.91
Mark up for direct costs	94,775.09
Rent	15,831.30
Other Indirect costs	51,417.28
Total Indirect Costs	67,248.58
	1,109,774.58 (5)

Treasury  
2300415

	2018 Actuals	2018 LE	Favorable (Unfavorable)
603000 Salaries	165,770.09	164,972.02	(798.07)
604000 Payroll Taxes	14,068.55	13,584.03	(484.52)
605100 BI Awards (B-Points)	500.00	-	(500.00)
606000 Annual Bonus	25,670.00	25,755.93	85.93
606400 Travel Other	1,250.00	-	(1,250.00)
606800 Office Supplies	283.67	141.83	(141.84)
607050 Canned Software	6,179.05	6,179.05	-
792000 Fringe Benefits	40,193.72	40,687.42	493.70
792010 Fleet Benefits	4,305.00	4,305.00	-
Subtotal Direct Costs	258,220.08	255,625.27	(2,594.81)
607510 Outside Rent	10,554.24	10,554.24	-
690600 Indirect Costs	14,008.93	18,459.09	4,450.16
Subtotal Indirect Costs	24,563.17	29,013.33	4,450.16
Total Cost	282,783.25	284,638.60	1,855.35
690300 TXP Direct Cost Assmt	-	(255,625.27)	(255,625.27)
690400 TXP Mark Up Assmt	-	(25,562.53)	(25,562.53)
690500 TXP Indirect Cost Assmt	-	(29,013.33)	(29,013.33)
Subtotal TXP Revenue	-	(310,201.13)	(310,201.13)
(Profit)	282,783.25	(25,562.53)	(308,345.78)
Headcount	2.00	2.00	2.00
FTE	2.50	2.50	2.50

% Allocation:

	T1	T2	1/2 of T3 (2)
PPLP	70%	55%	80%
Mundi - Chargeback to PPLP (3)	15%	10%	0%
PRALP	2%	2%	10%
Coventry	10%	30%	10%
OSR	3%	3%	0%
	100%	100%	100%

(1) Expense on PPLP's books offset by the \$75k per year billed by PPLP to Mundi for Risk Management services.  
(2) Only half of T3s cost is included in Treasury, the other half is included in Accounts Payable.

\$ Allocation:

	2018 Actuals	
208 PPLP	66% (204,287.96)	258,220.08 Direct Costs
208 MundiPharma	11% (35,132.88)	284,042.09 Direct Costs + 10%
208 Rhodes Overage from TXP		24,563.17 Indirect Costs
Subtotal - PPLP and Associated Companies	To P (239,420.84)	308,605.26 Total
230 Coventry	17% (51,777.97)	
230 Rhodes Overage to PPLP		
403 OSR	3% (8,072.45)	
416 PRALP	3% (9,333.99)	
	97% (308,605.26)	

(4)

(3)





## Exhibit 1G: Intercompany transfers between Purdue and TXP Services Inc. for financial and tax services

In 2019, three additional charges (contractually required under the July 2018 service agreement as amended) were paid to TXP, totaling \$416,697. These were accounted for on PPLP's books (SAP company code 208) under account 200010 (Intercompany Accounts Payable) under vendor number 7010066 (TXP), as well as under account 102415 (Intercompany Account – TXP). The invoice and contract excerpt<sup>1</sup> for the two larger payments, as well as their SAP entries, are illustrated below.

**TXP SERVICES, INC.**  
One Stamford Forum, 201 Tresser Blvd; Stamford, CT 06901-3431

BILL TO: Purdue Pharma LP  
One Stamford Forum  
201 Tresser Blvd  
Stamford, CT 06901

SHIP TO:

INVOICE DATE: 6/10/2019

INVOICE # TXP-51

TERMS: Due Upon Receipt

Quantity	Description	Price	Total
	Special Fee per Shared Service Agreement		

Document Overview - Display

Doc. Type : ZP ( Payment posting ) Normal document  
Doc. Number : 2000156325 Company Code : 208 Fiscal Year : 2019  
Doc. Date : 06/21/2019 Posting Date : 06/21/2019 Period : 06  
Calculate Tax ☐  
Doc. Currency : USD  
Payment Run ID : 06/21/2019 - PAYS

Item	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	TX	Amount	Text
1	25	7010066	TXP SERVICES INC		GEN				
2	50	100010	Cash Concentration		GEN				

3. Compensation. Effective as of the Effective Date, Section 3 of the Services Agreement is hereby amended to:

(a) delete and replace in its entirety the number [REDACTED] in the second sentence of subsection (a) thereof with: [REDACTED];

(b) add a new subsection (e) after subsection (d) thereof that consists of the following words, numbers and punctuation:

“(e) A special one-time fee of [REDACTED] (the “Second Special Fee”), subject to any refunds owed to Purdue as described below. The Second Special Fee will be invoiced on August 7, 2019 and paid within five (5) business days. The parties agree that the Second Special Fee relates to a specific expense of TXP that is subject to one or more potential refunds. If at any time or from time to time TXP receives one or more refunds in

Document Overview - Display

Doc. Type : SA ( G/L account document ) Normal document  
Doc. Number : 100180759 Company Code : 208 Fiscal Year : 2019  
Doc. Date : 06/15/2019 Posting Date : 06/14/2019 Period : 06  
Calculate Tax ☐  
Ref. Doc. : CMS Overall No. : 0100180759208 19  
Doc. Currency : USD  
Doc. Hdr Text : CTW208 06052019-06142019

Item	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	TX	Amount	Text
72	50	100010	Cash Concentration		GEN			240,288.49	1503221404 TXP SERVICES INC ONE STAMFORD FORUM STA
73	50	100010	Cash Concentration		GEN				1503221404 TXP SERVICES INC ONE STAMFORD FORUM STA
378	40	102415	TXP Services		GEN			390,144.89	

<sup>1</sup>Per discussions with Purdue, no invoice was issued for the [REDACTED] “Second Special Fee” payment.

## Exhibit 1G: Intercompany transfers between Purdue and TXP Services Inc. for financial and tax services

Individual cash settlements for TXP's services were not performed up until 2014. The first chart below illustrates the cumulative balances, debits, and credits from 2008 to September 15, 2019 in account 102415 (Intercompany Accounts – TXP Services Inc.) across the "Purdue bank group" of companies.<sup>1</sup> The second chart illustrates charges to accounts 793160 (TXP Cost Assessment), 793170 (TXP Mark Up), and 200010 (Intercompany Accounts Payable) under vendor number 7010066 (TXP) for services provided by TXP to Purdue.

Account 102415 <sup>2</sup>	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	Totals
Prior Year Cumulative Balance	\$ -	\$ (315,910)	\$ (109,254)	\$ (667,099)	\$ (448,295)	\$ (657,776)	\$ (590,983)	\$ (403,143)	\$ (534,907)	\$ (509,627)	\$ (784,515)	\$ (902,024)	
Debits	1,469,749	1,582,162	8,940,652	2,245,000	1,667,669	3,912,429	2,151,750	1,306,651	2,299,904	2,316,239	11,161,770	6,581,847	45,635,823
Credits	(1,785,659)	(1,375,506)	(9,498,497)	(2,026,196)	(1,877,151)	(3,845,636)	(1,963,911)	(1,438,415)	(2,274,625)	(2,591,126)	(11,279,279)	(4,954,515)	(44,910,515)
Ending Cumulative Balance	\$ (315,910)	\$ (109,254)	\$ (667,099)	\$ (448,295)	\$ (657,776)	\$ (590,983)	\$ (403,143)	\$ (534,907)	\$ (509,627)	\$ (784,515)	\$ (902,024)	\$ 725,308	
Cash Wire Sweep (CWS) Payments	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ 600,000	\$ 1,000,000	\$ 1,750,000	\$ 1,125,000	\$ 2,940,669	\$ 3,627,732	\$ 11,043,402
Other Non-CWS Debits	1,469,749	1,582,162	8,940,652	2,245,000	1,667,669	3,912,429	1,551,750	306,651	549,904	1,191,239	8,221,101	2,954,115	34,592,421
Total Debits	\$ 1,469,749	\$ 1,582,162	\$ 8,940,652	\$ 2,245,000	\$ 1,667,669	\$ 3,912,429	\$ 2,151,750	\$ 1,306,651	\$ 2,299,904	\$ 2,316,239	\$ 11,161,770	\$ 6,581,847	\$ 45,635,823
Accounts 793160, 793170, and 200010	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	Totals
TXP Assessments and Service Charges	\$ 1,038,363	\$ 971,339	\$ 1,876,315	\$ 1,908,805	\$ 1,870,552	\$ 1,849,805	\$ 1,262,983	\$ 1,226,247	\$ 1,388,196	\$ 1,555,265	\$ 2,502,912	\$ 2,559,793	\$ 20,010,575

<sup>1</sup>PPLP charges TXP for various costs such as pension, software, employee compensation, intercompany interest, etc. Charges and funding for these other items, along with adjusting journal entries (e.g. reclassifications, consolidating entries, etc.) represent the remaining portion of the activity in account 102415 for various SAP company codes which make up the "Purdue bank group" of companies (as defined below). Per discussions with Purdue and TXP, no formal agreements exist for these arrangements prior to July of 2018. Beginning July 1, 2018, the nature and amounts charges for these shared services were defined in the July 2018 services agreement.

<sup>2</sup>Represents the aggregate debits, credits, and balances on account 102415 across SAP company codes 208, 211, 213, 219, 225, 231, 240, 241, 256, 257, 258, 307, 313, and 318.





## Exhibit 1H: Intercompany transfers between Purdue and Mundipharma Research Limited for R&D services

On September 17, 2010, Purdue entered into a research services agreement with Mundipharma Research Limited, the service provider, which replaced the 2003 agreement. The agreement was amended in March 2017 and February 2018, adding and replacing the covered projects listed in Schedule 2 of the agreement. All other terms and conditions remain unchanged.

### RESEARCH SERVICES AGREEMENT

THIS AGREEMENT (this "Agreement") is entered into as of *17 September* 2010 by and between PURDUE PHARMA LP, a limited partnership having its place of business at One Stamford Forum, Stamford, CT 06901-3431, USA ("Customer"), and MUNDIPHARMA RESEARCH LIMITED, company no. 04608592, having its registered office at Cambridge Science Park, Milton Road, Cambridge CB4 0AB ("Service Provider")

#### WHEREAS:

- A. Customer is in the business of distributing pharmaceutical products.
- B. Service Provider is in the business of providing clinical research and development services.
- C. Customer and Service Provider entered into a research services agreement effective 1<sup>st</sup> January 2003 (the "2003 Research Services Agreement") pursuant to which Customer appointed Service Provider to provide it with clinical research and development services.
- D. Customer and Service Provider desire to amend and restate the 2003 Research Services Agreement to set forth revised terms and conditions upon which Service Provider will provide clinical research and development services to the Customer with effect from 1<sup>st</sup> January 2010.

### SCHEDULE 2

#### Product/Projects

- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]
- [REDACTED]



## Exhibit 1H: Intercompany transfers between Purdue and Mundipharma Research Limited for R&D services

Pursuant to the research services agreement, Purdue pays Mundipharma Research Limited i) costs and expenses and ii) [REDACTED] of such costs and expenses as a service charge on a monthly basis.

### 7. INVOICES AND PAYMENT

- 7.1 Within thirty days of the end of each calendar month, Service Provider shall submit to Customer an invoice showing the actual costs and expenses incurred by Service Provider in providing Services during such calendar month and supported by materials in substantially the same form as set out in Schedule 5 and containing a service charge in the amount of [REDACTED] of such costs and expenses save where research services are provided by an Associate Approved Sub-Contractor in which event the service charge will be in the amount of [REDACTED] of the cost of such Associate Approved-Sub Contractor.

## Exhibit 1H: Intercompany transfers between Purdue and Mundipharma Research Limited for R&D services

From 2008 through September 15, 2019, Purdue was charged \$80.5 million for the research services provided (costs and expenses plus markups<sup>1</sup>) by Mundipharma Research Limited, through PPLP (SAP company code 208) and two of its subsidiaries: PPPLP (SAP company code 313) and Imbrium Therapeutics L.P. ("Imbrium") (SAP company code 256).

Year	SAP Company Code			Total
	208	313	256	
2008	\$ 15,325,659	\$ -	\$ -	\$ 15,325,659
2009	8,404,405	-	-	8,404,405
2010	5,799,177	-	-	5,799,177
2011	3,333,509	-	-	3,333,509
2012	3,988,844	-	-	3,988,844
2013	3,283,531	-	-	3,283,531
2014	2,528,567	3,795,167	-	6,323,734
2015	1,132,803	5,382,312	-	6,515,115
2016	2,383,248	7,644,617	-	10,027,865
2017	3,865,134	6,796,256	-	10,661,390
2018	5,425,366	373,125	-	5,798,491
2019	563,751	443,998	47,984	1,055,733
<b>Total</b>	<b>\$ 56,033,992</b>	<b>\$ 24,435,476</b>	<b>\$ 47,984</b>	<b>\$ 80,517,452</b>

<sup>1</sup>Per discussion with Purdue, the █████ markups are included in the total invoiced amount, and not as shown as a separate line item. As such, the service charges are not separately discernable in SAP.

## Exhibit 1H: Intercompany transfers between Purdue and Mundipharma Research Limited for R&D services

According to PPLP's accounting records in SAP, PPLP (SAP company code 208) recognized the vendor payments related to R&D services from Mundipharma Research Limited (vendor ID 1027657) as follows.

Vendor Line Item Display

</

## Exhibit 1H: Intercompany transfers between Purdue and Mundipharma Research Limited for R&D services

According to PPPLP's accounting records in SAP, PPPLP (SAP company code 313) recognized the vendor payments related to R&D services from Mundipharma Research Limited (vendor ID 1027657) as follows.

Vendor		1027657							
Company Code		313							
Name		MUNDIPHARMA RESEARCH LTD							
City		CAMBRIDGE							

St	Assignment	DocumentNo	Type	Doc. Date	S	DD	Amount in local cur.	LCurr	Clrng doc.	Text
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900003223	RE	10.10.2017			703.176,51-	USD	1500000381	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900003246	RE	07.11.2017			446.048,09-	USD	1500000382	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900003296	RE	07.12.2017			172.380,80	USD	1500000385	CREDIT
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900003319	RE	31.01.2018			11.359,86	USD	1500000385	CREDIT
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900003342	RE	08.03.2018			568.200,46-	USD	1500000385	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900003407	RE	07.06.2018			170.237,02-	USD	1500000389	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900003485	RE	07.06.2018			591.981,44	USD	1500000391	CREDIT
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900003486	RE	10.05.2018			121.115,84-	USD	1500000391	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900003487	RE	09.04.2018			349.980,08-	USD	1500000391	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900003502	RE	07.08.2018			47.376,08-	USD	1500000391	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900003553	RE	10.09.2018			47.495,81	USD	1500000391	CREDIT
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900003572	RE	07.11.2018			33.762,91	USD	1500000391	CREDIT
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900003573	RE	08.10.2018			33.139,86	USD	1500000391	CREDIT
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900003614	RE	10.12.2018			6.336,20-	USD	1500000391	Clinical Pharmacology and Research Charges 11-2018
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900003630	RE	06.02.2019			26.896,98-	USD	1500000391	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900003632	RE	06.02.2019			417.101,13-	USD	1500000391	
* <input checked="" type="checkbox"/>							24.435.475,56-	USD		
** Account 1027657							24.435.475,56-	USD		

## Exhibit 1H: Intercompany transfers between Purdue and Mundipharma Research Limited for R&D services

According to Imbrium's accounting records in SAP, Imbrium (SAP company code 256) recognized the vendor payments related to R&D services from Mundipharma Research Limited (vendor ID 1027657) as follows.

Vendor		1027657								
Company Code		256								
Name		MUNDIPHARMA RESEARCH LTD								
City		CAMBRIDGE								

St	Assignment	DocumentNo	Type	Doc. Date	S	DD	Amount in local cur.	LCurr	Clrng doc.	Text
	<input type="checkbox"/> <input checked="" type="checkbox"/> SCAN	4900000078	RE	31.12.2018			47.984,10-	USD	1500000005	
*	<input checked="" type="checkbox"/>						47.984,10-	USD		
** Account 1027657							47.984,10-	USD		



## Exhibit 1H: Intercompany transfers between Purdue and Mundipharma Research Limited for R&D services

According to PPLP's and PPPLP's accounting records in SAP, PPLP (SAP company code 208) and PPPLP (SAP company code 313) recognized the expenses related to R&D services from Mundipharma Research Limited through G/L account 800100 (Foreign Other Expense). 2018 is illustrated below.<sup>1</sup>

G/L Account Company Code		800100 *		Foreign Other Expense						
CoCd	DocumentNo	Pstng Date	Doc. Date	Type	Cost Ctr	Reference	Account	Profit Ctr	Text	Amount in local cur.
<input type="checkbox"/> 208	4900123106	15.03.2018	08.03.2018	RE	9005208	MRL18004	800100	GEN		361.843,58
<input type="checkbox"/> 313	4900003342	15.03.2018	08.03.2018	RE	9005313	MRL18010	800100	GEN		568.200,46
<input type="checkbox"/> 208	4900124671	01.05.2018	09.04.2018	RE	9005208	MRL18029	800100	GEN		311.615,79
<input type="checkbox"/> 313	4900003487	19.07.2018	09.04.2018	RE	9005313	MRL18035	800100	GEN		349.980,08
<input type="checkbox"/> 208	4900126214	19.06.2018	10.05.2018	RE	9005208	MRL18049	800100	GEN		166.379,24
<input type="checkbox"/> 313	4900003486	18.07.2018	10.05.2018	RE	9005313	MRL18045	800100	GEN		121.115,84
<input type="checkbox"/> 208	4900126166	18.06.2018	07.06.2018	RE	9005208	MRL18062	800100	GEN		461.648,90
<input type="checkbox"/> 208	4900127170	19.07.2018	07.06.2018	RE	9005208	MRL18077	800100	GEN		446.565,63
<input type="checkbox"/> 313	4900003485	18.07.2018	07.06.2018	RE	9005313	MRL18074	800100	GEN		591.981,44-
<input type="checkbox"/> 313	4900003407	18.06.2018	07.06.2018	RE	9005313	MRL18059	800100	GEN		170.237,02
<input type="checkbox"/> 208	4900127911	16.08.2018	07.08.2018	RE	9005208	MRL18092	800100	GEN		991.911,91
<input type="checkbox"/> 313	4900003502	15.08.2018	07.08.2018	RE	9005313	MRL18089	800100	GEN		47.376,08
<input type="checkbox"/> 208	4900129132	08.10.2018	10.09.2018	RE	9005208	MRL18107	800100	GEN		1.170.529,61
<input type="checkbox"/> 313	4900003553	04.10.2018	10.09.2018	RE	9005313	MRL18113	800100	GEN		47.495,81-
<input type="checkbox"/> 208	4900130233	28.11.2018	08.10.2018	RE	9005208	MRL18124	800100	GEN		5.570,45
<input type="checkbox"/> 313	4900003573	28.11.2018	08.10.2018	RE	9005313	MRL18129	800100	GEN		33.139,86-
<input type="checkbox"/> 208	4900130423	06.12.2018	07.11.2018	RE	9005208	MRL18139	800100	GEN		603.091,01
<input type="checkbox"/> 313	4900003572	28.11.2018	07.11.2018	RE	9005313	MRL18145	800100	GEN		33.762,91-
<input type="checkbox"/> 208	4900130817	14.12.2018	10.12.2018	RE	9005208	MRL18155	800100	GEN	Clinical Pharmacology Research Charges for 11-2018	295.069,49
<input type="checkbox"/> 313	4900003614	14.12.2018	10.12.2018	RE	9005313	MRL18161	800100	GEN	Clinical Pharmacology and Research Charges 11-2018	6.336,20
<input checked="" type="checkbox"/> *										5.773.280,64

Note:

- Several G/L accounts were used to book the research service expenses before 2017. For example: 205110 - Accrued Other / 607330 - Subscriptions-Info Svc / 608640 - Outside Services / 609530 - Nonclinical Outsourcing / 800000 - Misc. Charge/Expense.

<sup>1</sup>In addition to the transactions in account 800100 illustrated in this screenshot, one transaction for \$25,210.13 was recognized in account 607330 in 2018. The sum of these transactions equals \$5,798,491, which ties to the amount for 2018 in the table on slide 135.

## Exhibit 1H: Intercompany transfers between Purdue and Mundipharma Research Limited for R&D services

Cash payments were recognized in PPLP's accounting records as follows. The final invoice sent to PPLP in 2018 is illustrated below.

Account Number	Account Description	DR	CR
Invoice received:			
800100	Foreign Other Expense	\$ 295,069	
200011	Account Payable Intercompany Foreign		\$ (295,069)
Cash paid:			
200011	Account Payable Intercompany Foreign	\$ 295,069	
700520	Gain/Loss on Exchange (Realized)	\$ 5,737	
100010	Cash Concentration		\$ (300,807)

## Exhibit 1H: Intercompany transfers between Purdue and Mundipharma Research Limited for R&D services

These entries appears in SAP as follows. The final invoice sent to PPLP in 2018 is illustrated below.

Invoice received:

Doc.Type : RE ( Invoice - gross ) Normal document					
Doc. Number	4900130817	Company Code	208	Fiscal Year	2018
Doc. Date	10.12.2018	Posting Date	14.12.2018	Period	12
Calculate Tax	<input type="checkbox"/>				
Ref.Doc.	MRL18155				
Doc. Currency	GBP				
Doc. Hdr Text	ARIBA_P2F				

Vendor	1027657	MUNDIPHARMA RESEARCH LTD	G/L Acc.	200011
Company Code	208	194 CAMBRIDGE SCIENCE PARK		
Purdue Pharma L.P.		CAMBRIDGE		
Doc. no.	4900130817			

Line Item 1 / Invoice / 31					
Amount	233.310,00	GBP	Amount in LC	295.069,49	USD
Tax code	U1				

G/L Acct CoCd Long Text		
200011	208	Accounts Payable Intercompany Foreign

Itm	PK	Account	Account short text	Amount in LC	Text
1	31	1027657	MUNDIPHARMA RESEARCH	295.069,49	Clinical Pharmacology Research Charges for 11-2018
2	81	800100	Foreign Other Exp.	295.069,49	Clinical Pharmacology Research Charges for 11-2018

Cash paid:

Doc.Type : KZ ( Vendor payment ) Normal document					
Doc. Number	1500012661	Company Code	208	Fiscal Year	2019
Doc. Date	16.01.2019	Posting Date	15.02.2019	Period	02
Calculate Tax	<input type="checkbox"/>				
Ref.Doc.	MRL18155				
Doc. Currency	GBP				

Vendor	1027657	MUNDIPHARMA RESEARCH LTD	G/L Acc.	200011
Company Code	208	194 CAMBRIDGE SCIENCE PARK		
Purdue Pharma L.P.		CAMBRIDGE		
Doc. no.	1500012661			

Line Item 2 / Outgoing payment / 25					
Amount	233.310,00	GBP	Amount in LC	295.069,49	USD
Tax code					

Itm	PK	Account	Account short text	Amount in LC	Text
1	50	100010	Cash Concentration	300.806,58-	
2	25	1027657	MUNDIPHARMA RESEARCH	295.069,49	WIRE CLEARING
3	40	700520	Realized FX	5.737,09	

## Exhibit 1H: Intercompany transfers between Purdue and Mundipharma Research Limited for R&D services

These entries appears in SAP as follows. The first invoice sent to PPLP in 2008 is illustrated below.

Invoice received:

Doc.Type : KR ( Vendor invoice ) Normal document					Vendor 1027657 MUNDIPHARMA RESEARCH LTD	G/L Acc 200000
Doc. Number	1900043101	Company Code	208	Fiscal Year	2008	
Doc. Date	09.06.2008	Posting Date	14.07.2008	Period	07	
Calculate Tax	<input checked="" type="checkbox"/>					
Ref.Doc.	MR08060					
Doc. Currency	USD					

Line Item 1 / Invoice / 31		Amount 975.672,80 USD		Tax code 01	
----------------------------	--	-----------------------	--	-------------	--

Long Text	CoCd	G/L Acct
Accts Payable Trade	208	200000

Itm	PK	Account	Account short text	Amount	Text
1	31	1027657	MUNDIPHARMA RESEARCH	975.672,80-	RESEARCH CHARGES
2	40	205110	Accr. Other	975.672,80	RESEARCH CHARGES

Cash paid:

Doc.Type : KZ ( Vendor payment ) Normal document					Vendor 1027657 MUNDIPHARMA RESEARCH LTD	G/L Acc 200000
Doc. Number	1500002068	Company Code	208	Fiscal Year	2008	
Doc. Date	24.07.2008	Posting Date	25.07.2008	Period	07	
Calculate Tax	<input type="checkbox"/>					
Ref.Doc.	WIRE TRANSFER					
Doc. Currency	USD					

Line Item 3 / Outgoing payment / 25		Amount 11.125.443,07 USD		Tax code	
-------------------------------------	--	--------------------------	--	----------	--

Itm	PK	Account	Account short text	Amount	Text
1	50	100010	Cash Concentration	11.110.247,89-	
2	50	700520	Realized FX	15.195,18-	Foreign Exchange - Gain/Loss
3	25	1027657	MUNDIPHARMA RESEARCH	11.125.443,07	


  

Clearing Document	Document Number	Amount	Text
1500002068	1900043101	975.672,80	RESEARCH CHARGES
1500002068	1900043102	57.801,28	RESEARCH CHARGES
1500002068	1900043103	5.679.177,82	RESEARCH CHARGES
1500002068	1900043104	4.412.791,17	RESEARCH CHARGES
Total		11,125,443.07	

## Exhibit 1I: Intercompany transfers between Purdue and Mundipharma EDO GmbH for R&D services

On January 18, 2013, PPLP entered into a services agreement with Mundipharma EDO GmbH. On the same day, PPPLP entered into a similar services agreement with Mundipharma EDO GmbH.

Below is an excerpt of the agreement between PPLP and Mundipharma EDO GmbH.



THIS AGREEMENT is executed as of June 21, 2013 by and between:-

1. **MUNDIPHARMA EDO GMBH**, a Swiss company whose principal place of business is at St. Alban Rheinweg 74, Basel CH-4052 Switzerland ("Service Provider"); and
2. **PURDUE PHARMA L.P.**, a Delaware limited partnership whose principal place of business is at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901, USA ("Customer").

NOW, THEREFORE, it is agreed as follows:

1. Definitions and Interpretation

- (a) In this Agreement the following expressions shall have the meanings respectively set against them as follows:
  - (i) "Adjustment" has the meaning given such term in Clause 6(d) below;
  - (ii) "Confidential Information" has the meaning given such term in Clause 9(a) below;
  - (iii) "Document" shall include, in addition to any document in writing, any drawing, map, plan, diagram, design, picture or other image, tape, disk or other device or record embodying information in any form;
  - (iv) "Effective Date" means 18th January 2013;



## Exhibit 1I: Intercompany transfers between Purdue and Mundipharma EDO GmbH for R&D services

Pursuant to the services agreements, Purdue pays Mundipharma EDO GmbH, i) costs incurred and ii) [REDACTED] of costs as a markup. Per discussion with Purdue, Purdue pays the agreed estimated service fees in advance on a quarterly basis, and reconciles estimated versus actual service fees in the following quarter.

6. Price and Payment

- (a) With respect to the Term of this Agreement, the price for the Services provided hereunder from time to time shall be (i) the cost to Service Provider of providing the Services plus a markup in the amount of [REDACTED] of such cost and (ii) any direct costs incurred by Service Provider from a third party on behalf of Customer (together, the "Estimated Service Fees"). The Estimated Service Fees for the Term are set forth in Schedule 2.
- (b) Customer will be invoiced for the Services quarterly in advance and will pay the invoice within thirty (30) days, with payments due in amounts as set forth in Schedule 2 (as the same may be amended from time to time).

### SCHEDULE 2

#### Estimated Service Fees

Total	Q1 2013	Q2 2013	Q3 2013	Q4 2013
CHF 406,500.00	CHF 101,625.00	CHF 101,625.00	CHF 101,625.00	CHF 101,625.00

## Exhibit 1I: Intercompany transfers between Purdue and Mundipharma EDO GmbH for R&D services

From 2013 to September 15, 2019, Purdue was charged \$31.5 million (costs and markups<sup>1</sup>) for the research services provided by Mundipharma EDO GmbH, through PPLP (SAP company code 208) and two of its subsidiaries: PPPLP (SAP company code 313) and Imbrium (SAP company code 256).

Year	SAP Company Code			Total
	208	313	256	
2013	\$ 136,089	\$ 136,089	\$ -	\$ 272,178
2014	3,704,765	1,302,119	-	5,006,885
2015	406,205	2,043,446	-	2,449,651
2016	1,410,581	1,265,560	-	2,676,142
2017	3,603,299	2,324,353	-	5,927,652
2018	5,711,158	5,130,079	-	10,841,236
2019	-	5,570,794	(1,227,633)	4,343,161
<b>Total</b>	<b>\$ 14,972,098</b>	<b>\$ 17,772,440</b>	<b>\$ (1,227,633)</b>	<b>\$ 31,516,905</b>

<sup>1</sup>Per discussion with Purdue, the █████ markups are included in the total invoiced amount, and not shown as a separate line item. As such, the service charges are not separately discernable in SAP.

## Exhibit 1I: Intercompany transfers between Purdue and Mundipharma EDO GmbH for R&D services

According to PPLP's accounting records in SAP, PPLP (SAP company code 208) recognized the vendor payments related to R&D services from Purdue to Mundipharma EDO GmbH (vendor ID 1032927) as follows.

Vendor		1032927								
Company Code		208								
Name		MUNDIPHARMA EDO GMBH								
City		BASEL								

St	Assignment	DocumentNo	Type	Doc. Date	S	DD	Amount in local cur.	LCurr	Clrng doc.	Text
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900108489	RE	18.01.2017			1.459.911,49-	USD	2000130587	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900119467	RE	11.10.2017			1.489.209,64-	USD	2000135315	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900119468	RE	19.07.2017			1.489.209,64-	USD	2000135315	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900119491	RE	19.07.2017			585.155,34	USD	2000135315	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900119492	RE	11.10.2017			975.449,58	USD	2000135315	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900101796	RE	16.07.2016			650.506,28	USD	2000137730	CREDIT
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900111131	RE	18.04.2017			1.184.070,81	USD	2000137730	CREDIT
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900121988	RE	31.01.2018			34.415,82-	USD	2000137730	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900122005	RE	31.01.2018			1.032.527,66-	USD	2000137730	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900125413	RE	19.04.2018			977.155,76-	USD	2000141703	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900125445	RE	19.04.2018			147.242,45	USD	2000141703	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900127295	RE	03.07.2018			981.061,50-	USD	2000144199	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900127309	RE	03.07.2018			1.482.257,01-	USD	2000144199	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900129126	RE	02.10.2018			981.938,10-	USD	2000147294	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900129318	RE	02.10.2018			369.044,37-	USD	2000147557	
<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>						14.972.097,84-	USD		
** Account 1032927							14.972.097,84-	USD		

## Exhibit 1I: Intercompany transfers between Purdue and Mundipharma EDO GmbH for R&D services

According to PPPLP's accounting records in SAP, PPPLP (SAP company code 313) recognized the vendor payments related to R&D services from Purdue to Mundipharma EDO GmbH (vendor ID 1032927) as follows.

Vendor		1032927								
Company Code		313								
Name		MUNDIPHARMA EDO GMBH								
City		BASEL								
St	Assignment	DocumentNo	Type	Doc. Date	S	DD	Amount in local cur.	LCurr	Clrng doc.	Text
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900002870	RE	18.10.2016			564.880,54	USD	1500000378	CREDIT
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900002871	RE	31.12.2016			501.332,77	USD	1500000378	Credit Note No. 816031
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900002874	RE	18.10.2016			892.834,81-	USD	1500000378	Invoice No. 816026
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900002876	RE	18.01.2017			962.872,92-	USD	1500000378	Invoice No. 817001
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900002989	RE	18.04.2017			982.682,28-	USD	1500000380	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900002990	RE	18.04.2017			445.645,02	USD	1500000380	CREDIT
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900003247	RE	19.07.2017			396.946,30	USD	2000002983	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900003248	RE	19.07.2017			984.150,00-	USD	2000002983	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900003249	RE	11.10.2017			571.578,62	USD	2000002983	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900003250	RE	11.10.2017			982.196,28-	USD	2000002984	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900003320	RE	31.01.2018			38.344,52-	USD	2000002998	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900003321	RE	31.01.2018			1.634.658,78-	USD	2000002998	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900003398	RE	19.04.2018			1.546.996,08-	USD	2000003017	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900003403	RE	19.04.2018			603.433,58	USD	2000003017	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900003488	RE	03.07.2018			416.637,75	USD	2000003028	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900003490	RE	03.07.2018			1.553.179,50-	USD	2000003028	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900003552	RE	02.10.2018			177.596,22	USD	2000003038	
<input type="checkbox"/>	<input checked="" type="checkbox"/> SCAN	4900003557	RE	02.10.2018			1.554.567,30-	USD	2000003038	
<input checked="" type="checkbox"/> *	<input checked="" type="checkbox"/>						12.201.646,51-	USD		

## Exhibit 1I: Intercompany transfers between Purdue and Mundipharma EDO GmbH for R&D services

According to Imbrium's accounting records in SAP, Imbrium (SAP company code 256) recognized the vendor payments related to R&D services from Purdue to Mundipharma EDO GmbH (vendor ID 1032927) as follows.

Vendor Line Item Display										
Vendor Company Code		1032927 256								
Name City		MUNDIPHARMA EDO GMBH BASEL								
St	Assignment	DocumentNo	Type	Doc. Date	S	DD	Amount in local cur.	LCurr	Clrng doc.	Text
<input type="checkbox"/>	<input checked="" type="radio"/> SCAN	4900000301	RE	08/07/2019		<input checked="" type="checkbox"/>	1,227,632.73	USD		CREDIT 919016
*	<input checked="" type="radio"/>						1,227,632.73	USD		
<input type="checkbox"/>	<input checked="" type="radio"/> SCAN	4900000147	RE	04/08/2019		<input type="checkbox"/>	2,761,641.86-	USD	1500000006	
<input type="checkbox"/>	<input checked="" type="radio"/> SCAN	4900000148	RE	12/31/2018		<input type="checkbox"/>	1,628,878.28-	USD	1500000006	
<input type="checkbox"/>	<input checked="" type="radio"/> SCAN	4900000149	RE	12/31/2018		<input type="checkbox"/>	139,415.28	USD	1500000006	
<input type="checkbox"/>	<input checked="" type="radio"/> SCAN	4900000151	RE	04/11/2019		<input type="checkbox"/>	1,319,688.79-	USD	1500000006	
*	<input checked="" type="radio"/>						5,570,793.65-	USD		
** Account 1032927							4,343,160.92-	USD		



## Exhibit 1I: Intercompany transfers between Purdue and Mundipharma EDO GmbH for R&D services

According to PPLP's and PPPLP's accounting records in SAP, PPLP (SAP company code 208) and PPPLP (SAP company code 313) were charged for R&D service by Mundipharma EDO through G/L account 800000 (Misc. Charge/Expense) and G/L account 690200 (International Charges/Credits). 2018 is illustrated below.

G/L Account		*								
Company Code		*								
CoCd	DocumentNo	Pstng Date	Doc. Date	Type	Cost Ctr	Reference	Account	Profit Ctr	Text	Amount in local cur.
<input type="checkbox"/> 208	4900121988	08.02.2018	31.01.2018	RE	9005208	818008	800000	GEN		34.415,82
<input type="checkbox"/> 208	4900122005	08.02.2018	31.01.2018	RE	9005208	818007	800000	GEN		1.032.527,66
<input type="checkbox"/> 313	4900003320	08.02.2018	31.01.2018	RE	9005313	818010	800000	GEN		38.344,52
<input type="checkbox"/> 313	4900003321	08.02.2018	31.01.2018	RE	9005313	818009	800000	GEN		1.634.658,78
<input type="checkbox"/> 208	4900125413	22.05.2018	19.04.2018	RE	9005208	818017	800000	GEN		977.155,76
<input type="checkbox"/> 208	4900125445	23.05.2018	19.04.2018	RE	9005208	818018	800000	GEN		147.242,45-
<input type="checkbox"/> 313	4900003398	22.05.2018	19.04.2018	RE	9005313	818019	800000	GEN		1.546.996,08
<input type="checkbox"/> 313	4900003403	23.05.2018	19.04.2018	RE	9005313	818020	800000	GEN		603.433,58-
<input type="checkbox"/> 208	4900127295	24.07.2018	03.07.2018	RE	4198EDB	818026	690200	EDB		981.061,50
<input type="checkbox"/> 208	4900127309	24.07.2018	03.07.2018	RE	4198EDB	818025	690200	EDB		1.482.257,01
<input type="checkbox"/> 313	4900003488	19.07.2018	03.07.2018	RE	4198EDS	818028	690200	EDS		416.637,75-
<input type="checkbox"/> 313	4900003490	24.07.2018	03.07.2018	RE	4198EDS	818027	690200	EDS		1.553.179,50
<input type="checkbox"/> 208	4900129126	08.10.2018	02.10.2018	RE	4198EDB	818034	690200	EDB		981.938,10
<input type="checkbox"/> 208	4900129318	16.10.2018	02.10.2018	RE	4198EDB	818039	690200	EDB		369.044,37
<input type="checkbox"/> 313	4900003552	04.10.2018	02.10.2018	RE	4198EDS	818040	690200	EDS		177.596,22-
<input type="checkbox"/> 313	4900003557	08.10.2018	02.10.2018	RE	4198EDS	818035	690200	EDS		1.554.567,30
<input checked="" type="checkbox"/>										10.841.236,40

## Exhibit 1I: Intercompany transfers between Purdue and Mundipharma EDO GmbH for R&D services

Cash payments were recognized as follows in PPLP's accounting records in SAP. The Q1 2018 advance payment is illustrated below.

Account Number	Account Description	DR	CR
Invoice received - Advance payment for R&D services:			
800000	Misc. Charges/Expenses	\$ 1,032,528	
200011	Account Payable Intercompany Foreign		\$ (1,032,528)
Cash paid:			
200011	Account Payable Intercompany Foreign - Example	\$ 1,032,528	
200011	Account Payable Intercompany Foreign - Other R&D services related		\$ (371,517)
700520	Gain/Loss on Exchange (Realized)		\$ (35,325)
100010	Cash Concentration		\$ (625,685)

Clearing Document	Document Number	Amount	Text
2000137730	4900122005	1,032,527.66	Agreed advance payment - 1Q2018
2000137730	4900101796	-650,506.28	True-up - 4Q2016
2000137730	4900111131	-1,184,070.81	True-up - 1Q2017
2000137730	1500012124	1,428,643.83	Agreed advance payment - 4Q2017
2000137730	4900121988	34,415.82	Agreed additional payment - 4Q2017

Total:  
\$ - 371,517

## Exhibit 1I: Intercompany transfers between Purdue and Mundipharma EDO GmbH for R&D services

These entries appear in SAP in PPLP's accounting records (SAP company code 208) through G/L account 200011 (Accounts Payable Intercompany Foreign). The Q1 2018 advance payment is illustrated below.

Invoice received - Advance payment for R&D services:

<b>Doc.Type : RE ( Invoice - gross ) Normal document</b>					
Doc. Number	4900122005	Company Code	208	Fiscal Year	2018
Doc. Date	31.01.2018	Posting Date	08.02.2018	Period	02
Calculate Tax	<input type="checkbox"/>				
Ref.Doc.	818007				
Doc. Currency	CHF				
Doc. Hdr Text	ARIBA_F2F				

Vendor	1032927	MUNDIPHARMA EDO GMBH	G/L Acc	200011
Company Code	208	ST ALBAN RHEINWEG 74		
Purdue Pharma L.P.	BASEL			
Doc. no.	4900122005			
Line Item 1 / Invoice / 31				
Amount	974.000,00	CHF	Amount in LC	1.032.527,66 USD
Tax code	U1			

G/L Acct	CoCd	Long Text
200011	208	Accounts Payable Intercompany Foreign

Itm	PK	Account	Account short text	Amount in LC	Text
1	31	1032927	MUNDIPHARMA EDO GMBH	1.032.527,66-	
2	81	800000	Misc. Charge/Expense	1.032.527,66	

Cash paid:

<b>Doc.Type : ZP ( Payment posting ) Normal document</b>					
Doc. Number	2000137730	Company Code	208	Fiscal Year	2018
Doc. Date	09.02.2018	Posting Date	09.02.2018	Period	02
Calculate Tax	<input type="checkbox"/>				
Doc. Currency	CHF				
Payment Run ID	09.02.2018 - PAY12				

Vendor	1032927	MUNDIPHARMA EDO GMBH	G/L Acc	200011
Company Code	208	ST ALBAN RHEINWEG 74		
Purdue Pharma L.P.	BASEL			
Doc. no.	2000137730			
Line Item 1 / Outgoing payment / 25				
Amount	585.316,00	CHF	Amount in LC	661.010,22 USD
Tax code				

Itm	PK	Account	Account short text	Amount in LC	Text
1	25	1032927	MUNDIPHARMA EDO GMBH	661.010,22	
2	50	100010	Cash Concentration	625.685,24-	
3	50	700520	Realized FX	35.324,98-	

Clearing Document	Document Number	Amount	Text
2000137730	4900122005	1,032,527.66	Agreed advance payment - 1Q2018
2000137730	4900101796	-650,506.28	True-up - 4Q2016
2000137730	4900111131	-1,184,070.81	True-up - 1Q2017
2000137730	1500012124	1,428,643.83	Agreed advance payment - 4Q2017
2000137730	4900121988	34,415.82	Agreed additional payment - 4Q2017
Total		661,010.22	

## Exhibit 1I: Intercompany transfers between Purdue and Mundipharma EDO GmbH for R&D services

These entries appear in SAP in PPLP's books (SAP company code 208) through G/L account 200011 (Accounts Payable Intercompany Foreign). An example of a Q4 2013 advance payment (the first payment) is shown below.

Invoice received - Advance payment for R&D services:

<b>Doc.Type : KR ( Vendor invoice ) Normal document</b> Doc. Number 1900117926 Company Code 208 Fiscal Year 2013 Doc. Date 01.10.2013 Posting Date 07.10.2013 Period 10 Calculate Tax <input checked="" type="checkbox"/> Ref.Doc. 813015A Doc. Currency USD					Vendor 1032927 MUNDIPHARMA EDO GMBH G/L Acc 200011 Company Code 208 ST ALBAN RHEINWEG 74 Purdue Pharma L.P. BASEL Doc. no. 1900117926	
Line Item 1 / Invoice / 31 Amount 136.089,04 USD Tax code						
					<b>G/L Acct CoCd Long Text</b> 200011 208 Accounts Payable Intercompany Foreign	
Itm	PK	Account	Account short text	Amount	Text	
1	31	1032927	MUNDIPHARMA EDO GMBH	136.089,04-		
2	40	800000	Misc. Charge/Expense	136.089,04		

Cash paid:

<b>Doc.Type : KZ ( Vendor payment ) Normal document</b> Doc. Number 1500008494 Company Code 208 Fiscal Year 2013 Doc. Date 09.10.2013 Posting Date 11.10.2013 Period 10 Calculate Tax <input type="checkbox"/> Ref.Doc. WIRE TRANSFER Doc. Currency USD					Vendor 1032927 MUNDIPHARMA EDO GMBH G/L Acc 200011 Company Code 208 ST ALBAN RHEINWEG 74 Purdue Pharma L.P. BASEL Doc. no. 1500008494	
Line Item 3 / Outgoing payment / 25 Amount 136.089,04 USD Tax code						
Itm	PK	Account	Account short text	Amount	Text	
1	50	100010	Cash Concentration	135.983,84-		
2	50	700520	Realized FX	105,20-		
3	25	1032927	MUNDIPHARMA EDO GMBH	136.089,04		

## Exhibit 1J: Intercompany transfers between Purdue and Mundipharma International UK for consulting and legal services

On July 4, 2012, Purdue entered into a services agreement with Mundipharma International Limited (UK) ("MIL UK"). Based on discussions with Purdue, the services provided included consulting services (i.e., management consulting and general and administrative services). On January 1, 2015, Purdue entered into a second services agreement with MIL UK which expanded the scope of services provided to Purdue to include legal services.

THIS AGREEMENT is executed as of July 4, 2012 by and between:-

1. **MUNDIPHARMA INTERNATIONAL LIMITED**, a company incorporated in England & Wales (Company number 02763367), whose registered office is at Cambridge Science Park, Milton Road, Cambridge CB4 0AB, England and whose VAT registration number is GB 599 7822 57 ("**Service Provider**"); and
2. **PURDUE PHARMA L.P.**, a Delaware limited partnership, whose principal place of business is at One Stamford Forum, Stamford, Connecticut 06901 ("**Customer**").

2. Range of Services

- (a) Service Provider will provide such of the Services as may be required by Customer.
- (b) Nothing in this Agreement shall prevent Customer from obtaining all or part of the Services from any other service provider or resource.

### SCHEDULE 1

#### Services

1.	Management Consultancy Services.
2.	General and Administration.

THIS AGREEMENT is executed as of January 1, 2015 by and between:

1. **MUNDIPHARMA INTERNATIONAL LIMITED**, a company incorporated in England & Wales (Company number 02763367), whose registered office is at Cambridge Science Park, Milton Road, Cambridge CB4 0AB, England and whose VAT registration number is GB 599 7822 57 ("**Service Provider**"); and
2. **PURDUE PHARMA L.P.**, a Delaware limited partnership, whose principal place of business is at One Stamford Forum, Stamford, Connecticut 06901, United States ("**Customer**").

2. Range of Services

- (a) Service Provider will provide such of the Services as may be required by Customer from time to time.
- (b) Nothing in this Agreement shall prevent Customer from obtaining all or part of the Services from any other service provider or resource.

### SCHEDULE 1

#### Services

1.	Management Consultancy Services.
2.	General and Administration.
3.	Legal Services.



## Exhibit 1J: Intercompany transfers between Purdue and Mundipharma International UK for consulting and legal services

Pursuant to the services agreement, Purdue agreed to pay an amount equal to the cost of the services plus 10%. Estimated payments were due quarterly (subject to change from the agreed-upon amounts listed in Schedule 2), and an annual reconciliation between estimated payments and actual costs following calendar year-end.

6. Price and Payment

- (a) With respect to the Term of this Agreement, the price for the Services provided hereunder from time to time shall be the sum of (i) the cost to Service Provider of providing the Services plus a service fee in the amount of ten percent (10%) of such cost and (ii) the amount of any disbursements (the "Estimated Payments"). The Estimated Payments for the Term are set forth in Schedule 2.
- (b) Customer will be invoiced for the Services quarterly in advance and will pay the invoice within thirty (30) days, with payments due in amounts as set forth in Schedule 2 (as the same may be amended from time to time).
- (c) Unless otherwise agreed each quarterly invoice will be for an amount equal to one quarter of the Estimated Payments. Service Provider will provide a mid-Year update to the Estimated Payments and will adjust each quarterly invoice to reflect such revised estimates.
- (d) On or before March 31st of the Year following the Term or by such date as agreed by the Parties, the Estimated Payments for the Term will be adjusted as follows (the "Adjustment"): (i) in the event that the sum of (a) the cost to Service Provider of providing the Services plus the service fee and (b) the amount of any disbursements, in each case, for the Term (the "Final Costs") is greater than the Estimated Payments for the Term, Service Provider will raise a supplemental invoice after the expiration of the Term to collect the difference between the Final Costs and the Estimated Payments, or (ii) in the event that the Final Costs are less than the Estimated Payments for the Term, Service Provider will raise a supplemental credit invoice after the expiration of the Term and Service Provider will pay Customer such credit amount within thirty (30) days.

**SCHEDULE 2**

**Estimated Payments**

Total	Q1 2012	Q2 2012	Q3 2012	Q4 2012
£104,000	£26,000	£26,000	£26,000	£26,000

# Exhibit 1J: Intercompany transfers between Purdue and Mundipharma International UK for consulting and legal services

From January 1, 2012 to November 21, 2018, Purdue paid \$4.5 million (costs and markups<sup>1</sup>) to Mundipharma pursuant to the consulting and legal services agreement.

Vendor Name	Vendor Number	Invoice Number	Invoice Date	Company Code	GL Account	Cost Center	Payment Date	Invoice Amount (Original Currency)	SAP Invoice Amount (USD) [1]	SAP Payment Amount (USD) [2]	Payment Year	Invoice Description	SAP Invoice Doc	SAP Payment Doc
MUNDIPHARMA INTERNATIONAL LTD	1008569	5204	7/16/2012	208	608660	2100208	8/20/2012	£ 78,000	\$ 121,865	\$ 122,421	2012	Q1-Q3 2012	1900100601	1500007015
MUNDIPHARMA INTERNATIONAL LTD	1008569	5227R	8/14/2012	208	608660	2301208	9/14/2012	€ 920	\$ 1,133	\$ 1,184	2012	Meeting Expense	1900101492	1500007099
MUNDIPHARMA INTERNATIONAL LTD	1008569	5291	10/1/2012	208	608640	2100208	10/31/2012	£ 26,000	\$ 41,909	\$ 41,740	2012	Q4 2012	1900103959	1500007274
MUNDIPHARMA INTERNATIONAL LTD	1008569	5371R	11/30/2012	208	606300	2100208	11/12/2012	€ 1,750	\$ 2,291	\$ 2,271	2012	Meeting Expense	1900106195	1500007494
MUNDIPHARMA INTERNATIONAL LTD	1008569	5667	3/28/2013	208	608660	2100208	4/30/2013	£ 113,184	\$ 172,007	\$ 256,108	2013	2012 Settlement Amount	1900111022	1500007942
MUNDIPHARMA INTERNATIONAL LTD	1008569	5540	1/9/2013	208	608660	2100208	4/4/2013	£ 52,657	\$ 79,526	\$ 79,681	2013	Q1 2013	1900110363	1500007829
MUNDIPHARMA INTERNATIONAL LTD	1008569	5694	4/3/2013	208	608660	2100208	4/30/2013	£ 52,657	\$ 79,761	\$ -	2013	Q2 2013	1900111023	1500007942
MUNDIPHARMA INTERNATIONAL LTD	1008569	3742R	6/19/2013	208	609350	2100208	7/24/2013	€ 69	\$ 91	\$ 91	2013	Meeting Expense	1900113910	1500008204
MUNDIPHARMA INTERNATIONAL LTD	1008569	5772	7/1/2013	208	608660	2100208	7/31/2013	£ 58,788	\$ 89,199	\$ 90,725	2013	Q3 2013	1900114458	1500008257
MUNDIPHARMA INTERNATIONAL LTD	1008569	5920	10/1/2013	208	608660	2100208	11/5/2013	£ 54,701	\$ 87,223	\$ 87,571	2013	Q4 2013	1900118344	1500008577
MUNDIPHARMA INTERNATIONAL LTD	1008569	6085R	12/17/2013	208	608640	2100208	1/31/2014	£ 121	\$ 198	\$ -	2014	Meeting Expense	1900121857	1500008867
MUNDIPHARMA INTERNATIONAL LTD	1008569	6134R	12/17/2013	208	608660	2100208	1/31/2014	£ 888	\$ 1,455	\$ -	2014	Meeting Expense	1900121858	1500008867
MUNDIPHARMA INTERNATIONAL LTD	1008569	10090	3/28/2014	208	608660	2100208	11/26/2014	£ (81,142)	\$ (134,999)	\$ -	2014	2013 Settlement Amount (Credit)	1700002659	1500009667
MUNDIPHARMA INTERNATIONAL LTD	1008569	10027A	1/1/2014	208	205110		1/31/2014	£ 37,364	\$ 61,516	\$ 63,649	2014	Q1 2014	1900121862	1500008867
MUNDIPHARMA INTERNATIONAL LTD	1008569	10119A	4/1/2014	208	608660	2100208	11/26/2014	£ 37,364	\$ 62,067	\$ -	2014	Q2 2014	1900130601	1500009667
MUNDIPHARMA INTERNATIONAL LTD	1008569	10252	6/30/2014	208	608491	9004208	7/29/2014	£ 97,000	\$ 165,974	\$ -	2014	Celltrion HC	1900128922	1500009392
MUNDIPHARMA INTERNATIONAL LTD	1008569	10246	7/1/2014	208	100010		7/31/2014	£ 90,664	\$ 155,554	\$ 318,015	2014	Q3 2014	1900129636	1500009392
MUNDIPHARMA INTERNATIONAL LTD	1008569	10402	10/30/2014	208	608660	9004208	11/26/2014	£ 289,028	\$ 461,608	\$ 385,607	2014	Q4 2014	1900133368	1500009667
MUNDIPHARMA INTERNATIONAL LTD	1008569	10636	6/15/2015	208	608660	2100208	9/4/2015	£ (6,463)	\$ (10,233)	\$ -	2015	2014 Settlement Amount (Credit)	1700002944	1500010339
MUNDIPHARMA INTERNATIONAL LTD	1008569	10597	2/12/2015	208	608660	9004208	3/6/2015	£ 132,910	\$ 204,126	\$ 202,369	2015	Q1 2015	1900137358	1500009909
MUNDIPHARMA INTERNATIONAL LTD	1008569	10628	4/23/2015	208	608660	2100208	5/29/2015	£ 132,910	\$ 204,172	\$ 203,499	2015	Q2 2015	1900141273	1500010119
MUNDIPHARMA INTERNATIONAL LTD	1008569	10773	8/6/2015	208	608660	2301208	9/4/2015	£ 132,910	\$ 205,171	\$ 193,552	2015	Q3 2015	1900144125	1500010339
MUNDIPHARMA INTERNATIONAL LTD	1008569	10943	12/17/2015	208	609350	2301208	2/22/2016	€ 453	\$ 515	\$ 506	2016	Meeting Expense	1900150671	1500010757
MUNDIPHARMA INTERNATIONAL LTD	1008569	10807B	2/12/2016	208	608660	9004208	9/30/2016	£ 177,760	\$ 248,041	\$ 248,041	2016	Q4 2015	1900156524 / 1900150910	1500010758 / 1500011324
MUNDIPHARMA INTERNATIONAL LTD	1008569	011307D	11/23/2016	208	608660	9004208	12/23/2016	£ (75,440)	\$ (95,272)	\$ -	2016	2015 Settlement Amount (Credit)	4900105102	1500011522
MUNDIPHARMA INTERNATIONAL LTD	1008569	11062	2/23/2016	208	608660	9004208	1/27/2017	£ 149,303	\$ 183,035	\$ -	2017	Q1 2016	4900107024	1500011583
MUNDIPHARMA INTERNATIONAL LTD	1008569	11114	4/20/2016	208	608660	9004208	1/27/2017	£ 149,303	\$ 185,066	\$ 374,225	2017	Q2 2016	4900106946	1500011583
MUNDIPHARMA INTERNATIONAL LTD	1008569	11267	8/25/2016	208	608660	9004208	9/28/2016	£ 148,803	\$ 194,615	\$ 192,975	2016	Q3 2016	4900100860	1500011316
MUNDIPHARMA INTERNATIONAL LTD	1008569	11295	11/21/2016	208	608660	9004208	12/23/2016	£ 201,310	\$ 250,041	\$ 154,712	2016	Q4 2016	4900104368	1500011522
MUNDIPHARMA INTERNATIONAL LTD	1008569	11370	11/30/2016	208	608660	9004208	12/1/2017	£ 7,758	\$ 8,064	\$ 8,209	2017	Meeting Expense	4900105817	1500011538
MUNDIPHARMA INTERNATIONAL LTD	1008569	12024	11/3/2017	208	608660	9004208	12/5/2017	£ 158,162	\$ 208,957	\$ 213,803	2017	2016 Settlement	4900118825	1500012077
MUNDIPHARMA INTERNATIONAL LTD	1008569	11637	1/23/2017	208	608660	9004208	2/23/2017	£ 156,741	\$ 197,454	\$ 194,939	2017	Q1 2017	4900107463	1500011642
MUNDIPHARMA INTERNATIONAL LTD	1008569	11776	4/20/2017	208	608660	9004208	5/19/2017	£ 156,741	\$ 201,701	\$ 203,230	2017	Q2 2017	4900110981	1500011794
MUNDIPHARMA INTERNATIONAL LTD	1008569	11860	7/17/2017	208	608660	9004208	11/8/2017	£ (74,994)	\$ (97,690)	\$ -	2017	Q3 2017	4900114074	1500012045
MUNDIPHARMA INTERNATIONAL LTD	1008569	11964	9/26/2017	208	606400	4705208	10/27/2017	£ 1,703	\$ 2,008	\$ 1,993	2017	Meeting Expense	4900117594	1500012038
MUNDIPHARMA INTERNATIONAL LTD	1008569	11991	10/11/2017	208	608660	9004208	11/8/2017	£ 189,307	\$ 251,527	\$ 150,482	2017	Q4 2017	4900117423	1500012045
MUNDIPHARMA INTERNATIONAL LTD	1008569	SI000075	10/29/2018	208	608660	9004208	11/21/2018	£ 54,105	\$ 69,261	\$ -	2018	2017 Settlement	4900129639	1500012585
MUNDIPHARMA INTERNATIONAL LTD	1008569	12247	2/8/2018	208	608660	9004208	3/12/2018	£ 106,663	\$ 147,414	\$ 147,472	2018	Q1 2018	4900122108	1500012230
MUNDIPHARMA INTERNATIONAL LTD	1008569	12273	4/19/2018	208	608660	9004208	5/18/2018	£ 106,663	\$ 149,366	\$ 144,294	2018	Q2 2018	4900124454	1500012335
MUNDIPHARMA INTERNATIONAL LTD	1008569	12307	4/23/2018	208	606510	2130208	4/24/2018	£ 3,393	\$ 4,143	\$ 3,997	2018	Training Expense	4900124475	1500012360
MUNDIPHARMA INTERNATIONAL LTD	1008569	SI000013	8/21/2018	208	608660	9004208	9/20/2018	£ 106,663	\$ 137,285	\$ 140,433	2018	Q3 2018	4900128218	1500012503
MUNDIPHARMA INTERNATIONAL LTD	1008569	SI000056	10/22/2018	208	608660	9004208	11/21/2018	£ 194,783	\$ 249,973	\$ 320,319	2018	Q4 2018	4900129619	1500012585
MUNDIPHARMA INTERNATIONAL LTD	1008569	SC000019	12/31/2018	208	608660	9004208	Pmt Pending	£ (187,035)	\$ (239,337)	Pmt Pending	TBD	2018 credit	4900131285	Pmt Pending
MUNDIPHARMA INTERNATIONAL LTD	1008569	SI000361	1/31/2019	208	608660	9004208	Pmt Pending	£ 48,330	\$ 63,201	Pmt Pending	TBD	Q1 2019	4900131789	Pmt Pending
MUNDIPHARMA INTERNATIONAL LTD	1008569	SI000392	4/11/2019	208	608660	9004208	Pmt Pending	£ 48,330	\$ 63,287	Pmt Pending	TBD	Q2 2019	4900133105	Pmt Pending
MUNDIPHARMA INTERNATIONAL LTD	1008569	SI000458	4/30/2019	208	606400	2413208	Pmt Pending	£ 1,230	\$ 1,601	Pmt Pending	TBD	Meeting Expense	4900133589	Pmt Pending
MUNDIPHARMA INTERNATIONAL LTD	1008569	SC000020	6/28/2019	208	607060	2301208	Pmt Pending	\$ 8,300	\$ 8,300	Pmt Pending	TBD	Credit - IT / End User Charges	4900134484	Pmt Pending
<b>Total</b>										<b>\$ 4,548,110</b>				

<sup>1</sup>Per discussion with Purdue, the 10% markups are included in the total invoiced amount, and not as shown as a separate line item. As such, the service charges are not separately discernable in SAP.

## Exhibit 1J: Intercompany transfers between Purdue and Mundipharma International UK for consulting and legal services

Cash payments were recognized as follows in PPLP's accounting records in SAP. The first payment from 2012 is illustrated below.

Account Number	Account Description	DR	CR
608660	Consultants Fees and Expenses - Management	\$ 121,865	
200011	Accounts Payable (Intercompany Foreign)		\$ (121,865)
200011	Accounts Payable (Intercompany Foreign)	\$ 121,865	
700520	Realized FX Gain/Loss on Exchange	\$ 556	
100010	Cash Concentration		\$ (122,421)

## Exhibit 1J: Intercompany transfers between Purdue and Mundipharma International UK for consulting and legal services

These entries appear in SAP as follows:

**Document Overview - Display**

Doc.Type : KR ( Vendor invoice ) Normal document  
 Doc. Number 1900100601 Company Code 208 Fiscal Year 2012  
 Doc. Date 16.07.2012 Posting Date 01.08.2012 Period 08  
 Calculate Tax ☒  
 Ref.Doc. 5204  
 Doc. Currency USD

Item	FK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Ix	Amount	Text
1	31	1008569	MUNDIPHARMA INTERNAT		GEN			121.864,52-	
2	40	608660	Consultants - Mgmt.	2100208	GEN			121.864,52	

**Document Overview - Display**

Doc.Type : KZ ( Vendor payment ) Normal document  
 Doc. Number 1500007015 Company Code 208 Fiscal Year 2012  
 Doc. Date 15.08.2012 Posting Date 20.08.2012 Period 08  
 Calculate Tax ☐  
 Ref.Doc. WIRE TRANSFER  
 Doc. Currency USD

Item	FK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Ix	Amount	Text
1	50	100010	Cash Concentration		GEN			122.421,00-	
2	40	700520	Realized FX	2100208	GEN			556,48	
3	25	1008569	MUNDIPHARMA INTERNAT		GEN			121.864,52	

**Display Document: Line Item 001**

Vendor 1008569 MUNDIPHARMA INTERNATIONAL LTD G/L Acc 200011  
 Company Code 208 194 CAMBRIDGE SCIENCE PARK  
 Purdue Pharma LP, CAMBRIDGE Doc. no. 1900100601


Line Item 1 / Invoice / 31  
 Amount 121.864,52 USD

General Ledger Account (1): 1 Entry found  
 G/L account with delete/lock flag in chart of accounts Key words

Master records  
 Long Text ChAc DelI Pstg block Crtn.block Plan.block G/L Acct  
 Accounts Payable Intercompany Foreign PURD ☐ ☐ ☐ ☐ 200011

## Exhibit 1J: Intercompany transfers between Purdue and Mundipharma International UK for consulting and legal services

SAP contains support for all payments until the most recent payment on November 21, 2018.



Purdue Pharma LP  
201 One Stamford Forum  
Tresser Boulevard  
Stamford  
USA

Bill-to Customer No. [REDACTED]

Posting Date 22. October 2018  
Due Date 21. November 2018  
Payment Terms 30 days

**Invoice No. SI000056**  
**Sales - Invoice**  
Page 1 of 1

Mundipharma International Limited  
Unit 195, Cambridge Science Park  
Milton Road  
Cambridge  
Cambridgeshire CB4 0AB

Phone No. 01223 424211  
E-Mail finance@mundipharma.com

Bank [REDACTED]  
Account No. [REDACTED]  
Sort Code [REDACTED]  
SWIFT Code [REDACTED]  
IBAN [REDACTED]  
VAT Registration No. [REDACTED]

Description	Quantity	Unit of Measure	Unit Price	VAT %	Amount
Qtr 4 MINT charges	1		194,783.00		194,783.00
<b>Total GBP</b>					<b>194,783.00</b>

Doc.Type : RE ( Invoice - gross ) Normal document

Doc. Number	4900129619	Company Code	208	Fiscal Year	2018
Doc. Date	22.10.2018	Posting Date	29.10.2018	Period	10
Calculate Tax	<input type="checkbox"/>				
Ref.Doc.	SI000056				
Doc. Currency	GBP				
Doc. Hdr Text	ARIBA_P2F				

Item	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	31	1008569	MUNDIPHARMA INTERNAT		GEN		U1	194.783,00-	
2	40	608660	Consultants - Mgmt.	9004208	GEN		U1	207.151,72	
3	50	203150	Use Tax Payable		GEN		U1	2.368,72-	



## **Exhibit 1K: Intercompany transfers between Purdue and Mundipharma A.G. to manufacture and sell MS Contin in the United States**

On January 1, 2008, Purdue entered into a manufacturer's licensing agreement with Mundipharma A.G., the Licensor, for the right to manufacture and sell MS Contin, a morphine-based pain reliver, in the United States.

### **MANUFACTURER'S LICENCE AGREEMENT**

THIS AGREEMENT is entered with effect from the 1st day of January 2008 by and between **MUNDIPHARMA A.G.** of St. Alban-Rheinweg 74, CH-4006 Basel, Switzerland, **PURDUE PHARMA L.P.** of One Stamford Forum, Stamford, Connecticut 06901-3431, U.S.A., and **PLP ASSOCIATES HOLDINGS L.P.** of One Stamford Forum, Stamford, Connecticut 06901-3431, U.S.A.

### **ANNEX II**

The Preparation as set forth in the annexed Agreement shall consist of a pharmaceutical preparation as specified by Licensor containing as active principle the Product which is marketed in certain countries under the trademark MS CONTIN.

## Exhibit 1K: Intercompany transfers between Purdue and Mundipharma A.G. to manufacture and sell MS Contin in the United States

The MS Contin license agreement granted Purdue the following licenses:

### Grant of Licences

#### **Licence to manufacture, use and sell**

Licensor hereby grants the right to Licensee to manufacture, package, use, distribute, market and sell within the Territory the Preparation under the Know-how, Trademarks and Patents as hereinafter provided.

#### **Licence of Know-how**

Licensor hereby licenses Licensee to use the Know-how for the purpose of manufacturing, packaging, using, distributing, marketing and selling the Preparation in the Territory but for no other purpose whatsoever. Nothing herein contained shall prohibit Licensor from licensing the Know-how or any part thereof to any other party for any purpose whatsoever.

#### **Licence of Trademarks**

Licensor hereby licenses Licensee to use and Licensee shall use the Trademarks in connection with the promotion and sale of the Preparation in the Territory, subject to the provision that such Trademarks shall be used in such manner as Licensor may determine and direct from time to time and provided always that the same are available and further provided that in the event that Licensor serves notice to terminate this Agreement Licensor shall have the right to use the Trademarks in the Territory and/or to

authorise others to use the Trademarks in the Territory following service of such notice.

#### **Licence of Patents**

Licensor hereby exclusively licenses Licensee to use the Patents for the purpose of manufacturing, packaging, using, distributing, marketing and selling the Preparation in the Territory during the life of the Patents or until termination of this Agreement whichever shall be earlier but for no other purpose whatsoever. Nothing herein contained shall prohibit Licensor from licensing the Patents to any other party for any other purpose whatsoever.

## **Exhibit 1K: Intercompany transfers between Purdue and Mundipharma A.G. to manufacture and sell MS Contin in the United States**

The MS Contin license agreement granted Purdue at least an 8-year term with extensions in 3-year periods.

### **DURATION**

This Agreement shall commence with effect from the 1st January 2008 and shall extend for an initial term of eight (8) years and shall continue thereafter for continuation terms of three (3) years unless either party shall give to the other at least six (6) months notice of intention to terminate prior to the end of the initial or any continuation term, in which event this Agreement shall terminate at the end of the term in which such notice is given.

## **Exhibit 1K: Intercompany transfers between Purdue and Mundipharma A.G. to manufacture and sell MS Contin in the United States**

Pursuant to the license agreement, Purdue agreed to pay a [REDACTED] royalty to Mundipharma A.G. on net sales for the licenses.

### Amount of Royalty

#### **Sales by Licensee to vendees other than to its Associated Companies and Licensor**

Should Licensee sell the Preparation to vendees other than to its Associated Companies and Licensor there shall accrue to Licensor from Licensee an earned royalty of [REDACTED] on the Net Sales of the Preparation.

#### **Sales by Licensee to its Associated Companies**

Should Licensee sell the Preparation to an Associated Company, or to a related person, firm or corporation (i.e., one which is not dealing at arm's length by reason of some common interest) then the royalties payable hereunder shall be based upon the Net Sales of such Associated Company, person, firm or corporation.

#### **Royalties on Sales of Sublicensee or Distributor**

In the event that Licensee markets the Preparation through a sublicensee or distributor the royalties payable hereunder shall be based upon the Net Sales of such sublicensee or distributor.

## Exhibit 1K: Intercompany transfers between Purdue and Mundipharma A.G. to manufacture and sell MS Contin in the United States

Under a prior version of the MS Contin license agreement, Purdue agreed to pay a [REDACTED] profit share on generic versions of MS Contin in addition to the existing [REDACTED] royalty on branded MS Contin. The [REDACTED] profit share was not explicitly discussed in the MS Contin license agreement; however, based on the prior agreement it was paid from 2008 to 2010.

### DECISION

August 9, 2005

#### MS Contin® License

Subject to confirmation that the following terms constitute an arms-length deal, it was recommended that the Amended License Agreement for Ms Contin® dated September 30, 1997 among Mundipharma A.G. ("Mundipharma"), PLP Associates Holdings L.P. ("PLP Associates") and Purdue Pharma L.P. ("PPLP") (the "License Agreement") be amended in an effort to handle the authorized generic version of MS Contin® as follows:

1. The License Agreement will be extended until September 30, 2011 to give PPLP time to recover its cost to transfer manufacturing from the Totowa facility to the Wilson facility;
2. [REDACTED] of PPLP's authorized generic profit share on the authorized generic version of MS Contin® will be paid to Mundipharma in addition to the current [REDACTED] royalty on the MS Contin® brand; and
3. Keeping the MS Contin® brand in distribution and launching an authorized generic version of MS Contin® will be agreed to be an appropriate promotion program.

(Recommendation of the Board of Directors of MNP Consulting Limited)



## **Exhibit 1K: Intercompany transfers between Purdue and Mundipharma A.G. to manufacture and sell MS Contin in the United States**

On October 1, 2016, the MS Contin license agreement was assigned by Purdue to Rhodes Pharma effective May 1, 2017. No consideration was enumerated in the assignment and assumption agreement.

### **ASSIGNMENT AND ASSUMPTION AGREEMENT (MS Contin®)**

This Assignment and Assumption Agreement (the "Agreement") effective October 1, 2016 (the "Effective Date") by and between Purdue Pharma L.P., a Delaware limited partnership ("Assignor"), and Rhodes Pharmaceuticals L.P., a Delaware limited partnership ("Assignee").

#### **2. Assignment; Inventory and Sales; Licenses; Transfer.**

(a) Assignment. Assignor does hereby convey, transfer, assign and deliver to Assignee, and Assignee does hereby accept from Assignor effective as of the Assignment Date all of Assignor's rights, title and interest of whatever kind and nature in and to the Products, including, but not limited to, the Know-How, Manufacturing Instructions, Patents, Specifications and, subject to Section 2(f), the Registrations for the Products (collectively, the "Assets"), to have and to hold the Assets hereby assigned, transferred and conveyed unto Assignee, its successors and assigns, to its and their own use and behalf forever. For the avoidance of doubt, "Assets" do not include the Regulatory Documentation for the Products or the Marks for the Products.

## Exhibit 1K: Intercompany transfers between Purdue and Mundipharma A.G. to manufacture and sell MS Contin in the United States

From January 1, 2008 to April 28, 2017, Purdue paid \$11.0 million under the MS Contin license agreement to Mundipharma A.G. including royalties and profit share.

Year	Quart	Payment Amount (US\$)	Payor	Payee	Payment Method	Payment Date	Payable Doc No.	Wire Transfer Doc No.	Profit Share (Generic)	Profit Share Royalty (15%)	Net Sales (Quarter)	PPD	Rebates	Net Sales less Discounts & Repates	Net Sales Royalty (10%)	Royalty Adjustment	Total Royalty
2009	1	\$ 583,985	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	4/22/2009	1900054875	1500002850	\$ 708,181	\$ 106,227	\$ 5,459,807	\$ (109,196)	\$ (573,037)	\$ 4,777,574	\$ 477,757		\$ 583,985
2009	2	453,424	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	7/22/2009	1900058579	1500003147	681,199	102,180	3,970,428	(79,409)	(378,581)	3,512,439	351,244		453,424
2009	3	481,461	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	11/2/2009	1900062628	1500003480	1,164,407	174,661	2,955,237	(59,105)	(171,864)	3,067,997	306,800		481,461
2009	4	541,452	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	2/9/2010	1900066274	1500003786	865,261	129,789	4,474,499	(89,490)	(268,380)	4,116,629	411,663		541,452
2010	1	604,287	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	4/30/2010	1900068765	1500004093	1,530,260	229,539	4,042,290	(80,846)	(213,961)	3,747,483	374,748		604,287
2010	2	681,848	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	7/30/2010	1900072120	1500004387	2,235,339	335,301	3,715,794	(74,316)	(176,010)	3,465,468	346,547		681,848
2010	3	490,553	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	10/29/2010	1900075566	1500004667	1,186,706	178,006	3,354,349	(67,087)	(161,795)	3,125,468	312,547		490,553
2010	4	483,383	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	2/25/2011	1900079849	1500005055	845,985	126,898	3,988,093	(79,762)	(343,475)	3,564,856	356,486		483,383
2011	1	324,695	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	4/29/2011	1900082304	1500005325	-	-	3,504,254	(86,809)	(170,492)	3,246,953	324,695		324,695
2011	2	254,239	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	7/28/2011	1900085677	1500005662	-	-	2,806,220	(73,543)	(190,284)	2,542,392	254,239		254,239
2011	3	352,964	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	10/31/2011	1900089494	1500006010	-	-	3,848,582	(88,925)	(230,017)	3,529,641	352,964		352,964
2011	4	289,811	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	1/31/2012	1900093268	1500006336	-	-	3,179,618	(30,835)	(250,675)	2,898,107	289,811		289,811
2012	1	273,340	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	5/4/2012	1900096999	1500006677	-	-	3,063,213	(64,327)	(265,484)	2,733,402	273,340		273,340
2012	2	316,696	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	7/30/2012	1900100509	1500006971	-	-	3,331,034	(69,952)	(94,125)	3,166,957	316,696		316,696
2012	3	283,599	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	11/13/2012	1900104392	1500007299	-	-	3,153,523	(66,224)	(251,305)	2,835,994	283,599		283,599
2012	4	302,485	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	1/31/2013	1900108145	1500007597	-	-	3,426,111	(103,903)	(297,355)	3,024,854	302,485		302,485
2013	1	209,822	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	4/30/2013	1900111229	1500007937	-	-	2,441,434	(62,970)	(280,242)	2,098,222	209,822		209,822
2013	2	283,882	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	7/31/2013	1900115338	1500008249	-	-	3,207,683	(71,028)	(297,832)	2,838,823	283,882		283,882
2013	3	262,170	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	11/8/2013	1900118873	1500008585	-	-	2,978,099	(65,931)	(290,472)	2,621,696	262,170		262,170
2013	4	312,621	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	1/30/2014	1900122293	1500008857	-	-	3,119,264	(76,992)	(83,940)	3,126,212	312,621		312,621
2014	1	234,448	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	4/30/2014	1900126001	1500009148	-	-	2,540,347	(66,846)	(129,024)	2,344,477	234,448		234,448
2014	2	276,808	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	7/31/2014	1900129689	1500009384	-	-	2,988,290	(85,011)	(135,198)	2,768,082	276,808		276,808
2014	3	242,002	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	10/31/2014	1900133225	1500009612	-	-	2,624,990	(77,508)	(127,465)	2,420,017	242,002		242,002
2014	4	303,752	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	1/30/2015	1900136894	1500009838	-	-	3,337,080	(91,833)	(207,729)	3,037,518	303,752		303,752
2015	1	176,609	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	4/30/2015	1900140043	1500010060	-	-	2,368,587	(72,088)	(260,000)	2,036,499	203,650	(27,040)	176,609
2015	2	181,600	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	7/30/2015	1900143273	1500010249	-	-	2,059,997	(56,386)	(187,614)	1,815,997	181,600		181,600
2015	3	248,300	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	10/31/2015	1900146516	1500010483	-	-	3,052,596	(69,235)	(500,361)	2,482,999	248,300		248,300
2015	4	197,349	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	1/28/2016	1900150078	1500010717	-	-	2,494,413	(57,043)	(463,879)	1,973,491	197,349		197,349
2016	1	263,288	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	4/28/2016	1900153111	1500010939	-	-	2,745,764	(64,220)	(48,662)	2,632,882	263,288		263,288
2016	2	232,473	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	7/28/2016	1900154996	1500011153	-	-	2,441,436	(54,570)	(62,140)	2,324,726	232,473		232,473
2016	3	201,854	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	10/28/2016	1900157018	1500011380	-	-	2,124,281	(49,441)	(56,300)	2,018,539	201,854		201,854
2016	4	471,518	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	1/31/2017	1900159411	1500011589	-	-	5,199,186	(56,178)	(427,828)	4,715,180	471,518		471,518
2017	1	187,567	Purdue Pharma L.P.	Mundipharma AG (SW)	Wire Transfer	4/28/2017	1900160869	1500011764	-	-	1,973,630	(46,647)	(51,315)	1,875,667	187,567		187,567
Total		\$ 11,004,285							\$ 9,217,340	\$ 1,382,601	\$ 105,970,129	\$ (2,347,656)	\$ (7,135,233)	\$ 96,487,240	\$ 9,648,724	\$ (27,040)	\$ 11,004,285

<sup>1</sup>In 2008, royalty and profit share payments of \$2.1 million were paid to Mundipharma A.G. by PLP Associates Holdings L.P., a limited partner of PRA L.P., the parent company of PPLP.

## Exhibit 1K: Intercompany transfers between Purdue and Mundipharma A.G. to manufacture and sell MS Contin in the United States

SAP contains invoice support for the royalty payments consistent with the terms of the MS Contin license agreement from the first royalty payment in 1Q2009.

Mundipharma AG  
ST Alban-Vorstadt  
Postfach CH-4006  
Basel, Switzerland

First Quarter 2009  
Per Actual Sales & Rebates

Product	Profit Share	Net Sales	2% Discount	Rebates	Net Sales Less Disc & Rebates	Royalty Rate	Total Royalty
MS Contin	-			\$			477,757.41
MS Contin Generic		-	-	-	-		106,227.15
<b>Grand Totals</b>	\$	\$	\$	\$	\$		\$ 583,984.56

PREPARED BY: [REDACTED]  
SIGNATURE: [REDACTED] DATE: April 10, 2009  
REVIEWED BY: [REDACTED]  
SIGNATURE: [REDACTED] DATE: 4/10/09

1400054375

P:\Finance\Share\Accounting Services\2009 Year End\Intercompany\1Q09\MAG\MAG ROYALTIES 1Q09  
MAG ROYALTIES 1Q09

## Exhibit 1K: Intercompany transfers between Purdue and Mundipharma A.G. to manufacture and sell MS Contin in the United States

SAP contains invoice support for the royalty payments consistent with the terms of the MS Contin license agreement through the last royalty payment made by Purdue in 1Q2017.

Purdue	
MS Contin Royalty to Mundipharma	
Q1 2017 MS Contin Royalty	
	<b>Q1 2017 YTD</b>
Gross Sales	\$ 1,973,629.63
Less: PPD	(46,647.45)
Less: Rebates	(51,315.46)
Net Sales	<u>\$ 1,875,666.72</u>
Royalty @ 10%	\$ 187,566.67
Less: Q1 Royalty Payment	-
Less: Q2 Royalty Payment	-
Less: Q3 Royalty Payment	-
Royalty Payment Due	<u>\$ 187,566.67</u>
Prepared by:	
Reviewed/Approved by:	

## Exhibit 1K: Intercompany transfers between Purdue and Mundipharma A.G. to manufacture and sell MS Contin in the United States

Cash payments were recognized as follows in PPLP's accounting records in SAP. The last royalty payment from 1Q2017 is illustrated below.

Account Number	Account Description	DR	CR
102710	Intercompany Account - Mundipharma AG, Switzerland	\$ 187,567	
200011	Accounts Payable (Intercompany Foreign)		\$ (187,567)
200011	Accounts Payable (Intercompany Foreign)	\$ 187,567	
100010	Cash Concentration		\$ (187,567)



## Exhibit 1K: Intercompany transfers between Purdue and Mundipharma A.G. to manufacture and sell MS Contin in the United States

These entries appear in SAP as follows:

**Document Overview - Display**

Doc.Type : KR ( Vendor invoice ) Normal document  
 Doc. Number 1900160869 Company Code 208 Fiscal Year 2017  
 Doc. Date 26.04.2017 Posting Date 27.04.2017 Period 04  
 Calculate Tax ☒  
 Ref.Doc. 042617  
 Doc. Currency USD

Item	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	31	1002047	MUNDIPHARMA AG (SW)		GEN		U1	187.566,67-	
2	40	102710	Mundi AG, Switz		GEN			187.566,67	

**Document Overview - Display**

Doc.Type : KZ ( Vendor payment ) Normal document  
 Doc. Number 1500011764 Company Code 208 Fiscal Year 2017  
 Doc. Date 28.04.2017 Posting Date 28.04.2017 Period 04  
 Calculate Tax ☐  
 Ref.Doc. WIRE TRANSFER  
 Doc. Currency USD

Item	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	50	100010	Cash Concentration		GEN			187.566,67-	
2	25	1002047	MUNDIPHARMA AG (SW)		GEN			187.566,67	

**Display Document: Line Item 001**

Vendor 1002047 MUNDIPHARMA AG (SW) G/L Acc 200011  
 Company Code 208 ST ALBAN-RHEINWEG 74  
 Purdue Pharma L.P. BASEL Doc. no. 1900160869

Line Item 1 / Invoice / 31  
 Amount 187.566,67 USD

General Ledger Account (1) 1 Entry found  
 G/L account with delete/lock flag in chart of accounts

Long Text ChAc DeFI Pstg block Crtn.block Plan.block G/L Acct  
 Accounts Payable Intercompany Foreign PURD 200011

1 Entry found

## Exhibit 1K: Intercompany transfers between Purdue and Mundipharma A.G. to manufacture and sell MS Contin in the United States

From May 1, 2017 to September 15, 2019, Rhodes Pharma (SAP company code 250) accrued \$1.3 million under the MS Contin license agreement in G/L account 205150 (Accrued Royalty Fees), but did not make any cash payments to Mundipharma A.G. during that time.

G/L Account Line Item Display														
G/L Account		205150		Accrued Royalty Fees										
Company Code		250												
CoCd	DocumentNo	Fstng Date	Doc. Date	Period	Year/month	Type	Cost Ctr	Reference	Account	Profit Ctr	Text	Amount in local cur.	LCurr	Order
<input type="checkbox"/>	250	100027404	28.02.2019	26.03.2019	2	2019/02	ZH	RP190251	205150	GEN	Accrue Profit Share Royalties for Feno	276.979,13	USD	
<input type="checkbox"/>	250	100027522	31.03.2019	02.04.2019	3	2019/03	ZH	RP190229	205150	GEN	Mar 2019 Royalty	208.675,10	USD	
<input type="checkbox"/>	250	100027913	30.04.2019	06.05.2019	4	2019/04	ZH	RP190429	205150	GEN	Apr 2019 Royalty	276.563,98	USD	
<input type="checkbox"/>	250	100027969	30.04.2019	08.05.2019	4	2019/04	SA	RP190429C	205150	GEN	Mar 2019 Feno PS	12.622,26	USD	
<input type="checkbox"/>	250	100027969	30.04.2019	08.05.2019	4	2019/04	SA	RP190429C	205150	GEN	Apr 2019 Feno PS	26.958,75	USD	
<input type="checkbox"/>	250	100027970	30.04.2019	08.05.2019	4	2019/04	SA	RP190429D	205150	GEN	Mar 2019 Paroxetine PS	6.456,87	USD	
<input type="checkbox"/>	250	100027970	30.04.2019	08.05.2019	4	2019/04	SA	RP190429D	205150	GEN	Apr 2019 Paroxetine PS	6.454,39	USD	
<input type="checkbox"/>	250	100027971	30.04.2019	08.05.2019	4	2019/04	SA	RP190429E	205150	GEN	Mar 2019 MS Contin PS	18.373,35	USD	
<input type="checkbox"/>	250	100027971	30.04.2019	08.05.2019	4	2019/04	SA	RP190429E	205150	GEN	Apr 2019 MS Contin PS	25.400,60	USD	
<input type="checkbox"/>	250	100027972	30.04.2019	08.05.2019	4	2019/04	SA	RP190430	205150	GEN	Royalties for Feno	75.336,56	USD	
<input type="checkbox"/>	250	100027973	30.04.2019	08.05.2019	4	2019/04	SA	RP190431	205150	GEN	Paroxetine PS Agreement	59.549,78	USD	
<input type="checkbox"/>	250	100027995	31.12.2017	09.05.2019	12	2017/12	ZH	RP171236C	205150	GEN	Reclass MS Contin Royalty	707.717,00	USD	
<input type="checkbox"/>	250	100027996	31.12.2018	09.05.2019	12	2018/12	ZH	RP181245C	205150	GEN	Reclass MS Contin Royalty	441.814,00	USD	
<input type="checkbox"/>	250	100028347	31.05.2019	06.06.2019	5	2019/05	SA	RP190529D	205150	GEN	May 2019 Paroxetine PS	11.342,47	USD	
<input type="checkbox"/>	250	100028348	31.05.2019	06.06.2019	5	2019/05	SA	RP190529E	205150	GEN	May 2019 MS Contin PS	35.852,35	USD	
<input type="checkbox"/>	250	100028352	31.05.2019	06.06.2019	5	2019/05	SA	RP190529C	205150	GEN	May 2019 Feno PS	20.816,99	USD	
<input type="checkbox"/>	250	100028319	31.05.2019	07.06.2019	5	2019/05	ZH	RP190529	205150	GEN	May 2019 Royalty	239.368,81	USD	
<input type="checkbox"/>	250	100028349	31.05.2019	07.06.2019	5	2019/05	SA	RP190531	205150	GEN	Paroxetine PS Agreement	59.549,78	USD	
<input type="checkbox"/>	250	100028349	31.05.2019	07.06.2019	5	2019/05	SA	RP190531	205150	GEN	Paroxetine PS Agreement Adj	59.549,78	USD	
<input type="checkbox"/>	250	100028326	31.05.2019	10.06.2019	5	2019/05	SA	RP190529F	205150	GEN	MS Contin Royalty reclass from Interco	1.149.531,00	USD	
<input type="checkbox"/>	250	100028381	31.12.2018	12.06.2019	12	2018/12	SA	RP180545CR	205150	GEN	MS Contin Royalty reclass from Interco	1.149.531,00	USD	
<input type="checkbox"/>	250	100028382	31.05.2019	12.06.2019	5	2019/05	SA	RP190529FR	205150	GEN	MS Contin Royalty reclass from Interco	1.149.531,00	USD	
<input type="checkbox"/>	250	100028623	30.06.2019	02.07.2019	6	2019/06	SA	RP190634	205150	GEN	Royalties for Feno	26.750,00	USD	
<input type="checkbox"/>	250	100028660	30.06.2019	02.07.2019	6	2019/06	SA	RP190629C	205150	GEN	June 2019 Feno Caps PS Exp	11.082,85	USD	
<input type="checkbox"/>	250	100028660	30.06.2019	02.07.2019	6	2019/06	SA	RP190629C	205150	GEN	June 2019 Feno Tabs PS Exp	2.280,19	USD	
<input type="checkbox"/>	250	100028661	30.06.2019	02.07.2019	6	2019/06	SA	RP190629D	205150	GEN	June 2019 Paroxetine PS	6.194,45	USD	
<input type="checkbox"/>	250	100028662	30.06.2019	02.07.2019	6	2019/06	SA	RP190629E	205150	GEN	June 2019 MS Contin PS	30.667,15	USD	
<input type="checkbox"/>	250	100028619	30.06.2019	03.07.2019	6	2019/06	ZH	RP190629	205150	GEN	June 2019 Royalty	293.742,78	USD	
<input type="checkbox"/>	250	100028689	30.06.2019	09.07.2019	6	2019/06	ZH	RP190629C	205150	GEN	Butrans AG Reclass to Interco	2.350.333,00	USD	
*												1.316.099,95	USD	

## **Exhibit 1L: Intercompany transfers between Purdue and Pharmaceutical Research Associates, Inc. for licensing the trademarks of Betadine and Senokot**

On November 29, 2006, Purdue Products L.P. (now known as Avrio Health) entered into license agreements with Pharmaceutical Research Associates, Inc. ("PRA Inc."), the Licensor, for the right to use the Betadine and Senokot trademarks.

### **AMENDED AND RESTATED LICENSE AGREEMENT** **(SENOKOT®)**

THIS AMENDED AND RESTATED LICENSE AGREEMENT (this "Agreement") is entered with effect from November 29, 2006 (the "Effective Date") by and between Pharmaceutical Research Associates, Inc., a New York corporation ("Licensor"), and Purdue Products L.P., a Delaware limited partnership ("Licensee").

#### **WITNESSETH:**

WHEREAS, The Purdue Frederick Company, a New York corporation ("Original Licensor"), and Licensee are parties to that certain License Agreement (Senokot®), including related Exhibits thereto, effective April 8, 2003 for the license of Product for human therapy (the "Original Agreement");

WHEREAS, Original Licensor has assigned to the Licensor all of its right, title and interest in and to the Original Agreement;

WHEREAS, Licensor and Licensee desire to amend and restate the Original Agreement to reflect the Original Licensor's foregoing assignment to the Licensor as a party to this Agreement;

### **AMENDED AND RESTATED LICENSE AGREEMENT** **(BETADINE®)**

THIS AMENDED AND RESTATED LICENSE AGREEMENT (this "Agreement") is entered with effect from November 29, 2006 (the "Effective Date") by and between Pharmaceutical Research Associates, Inc., a New York corporation ("Licensor"), and Purdue Products L.P., a Delaware limited partnership ("Licensee").

#### **WITNESSETH:**

WHEREAS, The Purdue Frederick Company, a New York corporation ("Original Licensor"), and Licensee are parties to that certain License Agreement (Betadine®), including related Exhibits thereto, effective April 8, 2003 for the license of Product for human therapy (the "Original Agreement");

WHEREAS, Original Licensor has assigned to the Licensor all of its right, title and interest in and to the Original Agreement;

WHEREAS, Licensor and Licensee desire to amend and restate the Original Agreement to reflect the Original Licensor's foregoing assignment to the Licensor as a party to this Agreement;

## **Exhibit 1L: Intercompany transfers between Purdue and Pharmaceutical Research Associates, Inc. for licensing the trademarks of Betadine and Senokot**

Per the agreements, the terms of licenses were for the commercial life of Betadine and Senokot with a royalty rate of [REDACTED] of Net Sales.

### **SECTION 4. DURATION**

This Agreement commenced with effect from the Effective Date and shall extend for the commercial life of the Product, unless Licensee shall give to Licensor notice of intention to terminate, in which event this Agreement shall terminate thirty (30) days after the date such notice is given.

### **SECTION 5. ROYALTIES**

5.1 Amount of Royalty. For the licenses granted under Section 2, Licensee shall pay to Licensor a royalty of [REDACTED] on the Net Sales of the Product in the Territory. In the event that Licensee distributes the Product through a sublicensee or distributor, the royalties payable hereunder shall be based on the Net Sales of such sublicensee or distributor.

## Exhibit 1L: Intercompany transfers between Purdue and Pharmaceutical Research Associates, Inc. for licensing the trademarks of Betadine and Senokot

From January 1, 2008 to September 15, 2019, Purdue was charged \$22.8 million by PRA Inc. for the use of the Betadine and Senokot trademarks.

Product Code	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	Total
BET - Betadine	\$ 668,206	\$ 616,099	\$ 742,896	\$ 771,008	\$ 765,972	\$ 907,630	\$ 812,491	\$ -	\$ -	\$ -	\$ 729,439	\$ 582,603	\$ 6,596,344
SEN - Senokot	1,873,809	1,155,397	1,369,662	1,221,731	934,166	1,129,092	973,077	-	-	-	1,238,654	899,801	10,795,390
GEN - General non product spec	-	-	-	-	-	-	-	1,833,050	1,838,701	1,766,378	-	-	5,438,129
<b>Total</b>	<b>\$ 2,542,015</b>	<b>\$ 1,771,497</b>	<b>\$ 2,112,558</b>	<b>\$ 1,992,739</b>	<b>\$ 1,700,138</b>	<b>\$ 2,036,722</b>	<b>\$ 1,785,568</b>	<b>\$ 1,833,050</b>	<b>\$ 1,838,701</b>	<b>\$ 1,766,378</b>	<b>\$ 1,968,093</b>	<b>\$ 1,482,404</b>	<b>\$ 22,829,863</b>



## Exhibit 1L: Intercompany transfers between Purdue and Pharmaceutical Research Associates, Inc. for licensing the trademarks of Betadine and Senokot

According to Purdue Products L.P.'s (SAP company code 307) accounting records in SAP, charges for royalties to Purdue Products from PRA Inc. were consolidated through G/L account 102190 (Intercompany Account - PRA Inc.). The screenshot below illustrates total royalty charges between January 1, 2008 and September 15, 2019.<sup>1</sup>

G/L Account Company Code		102190 307		PRA									
CoCd	DocumentNo	Postng Date	Doc. Date	Period	Year/month	Type	Cost Ctr	Reference	Account	Profit Ctr	Text	Amount in local cur.	LCurr
<input type="checkbox"/>	307	100030385	05/31/2015	06/08/2015	5	2015/05	SA	LMT 0515 100	102190	GEN	BET AND SEN ROYALTY 307 TO 190 2014 True Up	147,911.52-	USD
<input type="checkbox"/>	307	100024989	04/30/2013	05/07/2013	4	2013/04	SA	MG 0413 07	102190	GEN	BET AND SEN ROYALTY 307 TO 190 DEC 2012	147,748.66-	USD
<input type="checkbox"/>	307	100036028	02/28/2018	03/01/2018	2	2018/02	SA	LMT 001	102190	GEN	BET & SEN ROYALTY 307 TO 190 2018 True Up	147,327.06-	USD
<input type="checkbox"/>	307	100032096	02/29/2016	03/01/2016	2	2016/02	SA	LMT 001	102190	GEN	BET & SEN ROYALTY 307 TO 190 2015 True Up	147,287.38-	USD
<input type="checkbox"/>	307	100027590	09/30/2014	10/09/2014	9	2014/09	SA	MG 0914 19	102190	GEN	BET AND SEN ROYALTY 307 TO 190 SEPT 2014	147,172.04-	USD
<input type="checkbox"/>	307	100035943	01/31/2018	02/08/2018	1	2018/01	SA	LMT 001	102190	GEN	BET & SEN ROYALTY 307 TO 190 2017 True Up	147,045.35-	USD
<input type="checkbox"/>	307	100036320	07/31/2018	08/02/2018	7	2018/07	SA	LMT 001	102190	GEN	BET & SEN ROYALTY 307 TO 190 2018 True Up	146,750.87-	USD
<input type="checkbox"/>	307	100029302	01/31/2015	02/12/2015	1	2015/01	SA	LMT 0115 100	102190	GEN	BET AND SEN ROYALTY 307 TO 190 2014 True Up	146,346.00-	USD
<input type="checkbox"/>	307	100026828	12/31/2013	01/09/2014	12	2013/12	SA	MG 1213 08	102190	GEN	BET AND SEN ROYALTY 307 TO 190 DEC 2013	145,468.81-	USD
<input type="checkbox"/>	307	100035002	07/31/2017	08/02/2017	7	2017/07	SA	LMT 001	102190	GEN	BET & SEN ROYALTY 307 TO 190 2017 True Up	145,145.79-	USD
<input type="checkbox"/>	307	100026953	02/28/2014	03/04/2014	2	2014/02	SA	MG 0214 01	102190	GEN	BET AND SEN ROYALTY 307 TO 190 JAN 2014	144,475.18-	USD
<input type="checkbox"/>	307	100027010	02/28/2014	03/11/2014	2	2014/02	SA	MG 0214 11	102190	GEN	BET AND SEN ROYALTY 307 TO 190 JAN 2014	144,293.30-	USD
<input type="checkbox"/>	307	100029996	03/31/2015	04/08/2015	3	2015/03	SA	LMT 0315 100	102190	GEN	BET AND SEN ROYALTY 307 TO 190 2014 True Up	142,774.35-	USD
<input type="checkbox"/>	307	100031306	10/31/2015	11/09/2015	10	2015/10	SA	LMT 1015 100	102190	GEN	BET AND SEN ROYALTY 307 TO 190 2015 True Up	142,571.41-	USD
<input type="checkbox"/>	307	100021040	03/31/2012	03/31/2012	3	2012/03	SA	ROYALTY	102190	GEN	ROYALTY BET & SEN MAR-12	141,838.57-	USD
<input type="checkbox"/>	307	100029022	11/30/2014	12/04/2014	11	2014/11	SA	JAS 1114 105	102190	GEN	BET & SEN Royalty OCT 2014 from 307 to 190	141,793.62-	USD
<input type="checkbox"/>	307	100034613	04/30/2017	05/02/2017	4	2017/04	SA	LMT 001	102190	GEN	BET & SEN ROYALTY 307 TO 190 2017 True Up	141,487.67-	USD
<input type="checkbox"/>	307	100032959	07/31/2016	08/01/2016	7	2016/07	SA	LMT 001	102190	GEN	BET & SEN ROYALTY 307 TO 190 2016 True Up	140,463.51-	USD
<input type="checkbox"/>	307	100023088	09/30/2012	09/30/2012	9	2012/09	SA	ROYALTY	102190	GEN	BET AND SEN ROYALTY 307 TO 190 SEPT 2012	137,891.33-	USD
<input type="checkbox"/>	307	100035164	11/30/2017	12/01/2017	11	2017/11	SA	LMT 001	102190	GEN	BET & SEN ROYALTY 307 TO 190 2017 True Up	137,665.70-	USD
<input type="checkbox"/>	307	100032601	05/31/2016	06/02/2016	5	2016/05	SA	LMT 001	102190	GEN	BET & SEN ROYALTY 307 TO 190 2016 True Up	136,466.53-	USD
<input type="checkbox"/>	307	100025979	09/30/2013	10/04/2013	9	2013/09	SA	MG 0913 08	102190	GEN	BET AND SEN ROYALTY 307 TO 190 SEPT 2013	134,345.25-	USD
<input type="checkbox"/>	307	100029666	02/28/2015	03/10/2015	2	2015/02	SA	LMT 0215 100	102190	GEN	BET AND SEN ROYALTY 307 TO 190 2014 True Up	133,922.48-	USD
<input type="checkbox"/>	307	100017320	10/31/2010	10/31/2010	10	2010/10	SA	OCT10 ROYALTY	102190	GEN	"ROYALTY BET, SEN & XFR 307 TO 190 9/10"	133,919.81-	USD
<input type="checkbox"/>	307	100034250	02/28/2017	03/02/2017	2	2017/02	SA	LMT 001	102190	GEN	BET & SEN ROYALTY 307 TO 190 2016 True Up	133,449.20-	USD
<input type="checkbox"/>	307	100029070	12/31/2014	01/13/2015	12	2014/12	SA	JAS 1214 109	102190	GEN	BET AND SEN ROYALTY 307 TO 190 Dec 2014	132,006.38-	USD
<input type="checkbox"/>	307	100035199	12/31/2017	01/05/2018	12	2017/12	SA	LMT 001	102190	GEN	BET & SEN ROYALTY 307 TO 190 2017 True Up	130,630.38-	USD
<input type="checkbox"/>	307	100033937	01/31/2017	02/13/2017	1	2017/01	SA	LMT 001	102190	GEN	BET & SEN ROYALTY 307 TO 190 2016 True Up	129,363.27-	USD
<input type="checkbox"/>	307	100029071	12/31/2014	01/13/2015	12	2014/12	SA	JAS 1214 110	102190	GEN	BET AND SEN ROYALTY 307 TO 190 2014 True Up	128,223.45-	USD
<input type="checkbox"/>	307	100018032	02/28/2011	02/28/2011	2	2011/02	SA	ROYALTY	102190	GEN	BET AND SEN ROYALTY 307 TO 190	128,006.08-	USD
<input type="checkbox"/>	307	100016088	06/30/2010	06/30/2010	6	2010/06	SA	ROYALTY	102190	GEN	BET AND SEN ROYALTY 307 TO 190	125,904.53-	USD
<input type="checkbox"/>	307	100020866	01/31/2012	01/31/2012	1	2012/01	SA	ROYALTY	102190	GEN	BET AND SEN ROYALTY 307 TO 190 AUG-11	124,908.62-	USD
<input type="checkbox"/>	307	100018500	03/31/2011	03/31/2011	3	2011/03	SA	ROYALTY	102190	GEN	BET AND SEN ROYALTY 307 TO 190	124,332.73-	USD
<input type="checkbox"/>	307	100014606	01/31/2010	01/31/2010	1	2010/01	SA	ROYALTY	102190	GEN	BET AND SEN ROYALTY 307 TO 190	123,639.72-	USD
<input type="checkbox"/>	307	100013173	08/31/2009	08/31/2009	8	2009/08	SA	RECURRING	102190	GEN	BET AND SEN ROYALTY 307 TO 190	122,710.41-	USD
<input type="checkbox"/>	307	100035030	08/31/2017	09/05/2017	8	2017/08	SA	LMT 001	102190	GEN	BET & SEN ROYALTY 307 TO 190 2017 True Up	119,412.80-	USD
<input type="checkbox"/>	307	100031770	01/31/2016	02/18/2016	1	2016/01	SA	LMT 001	102190	GEN	BET & SEN ROYALTY 307 TO 190 2015 True Up	118,491.05-	USD
<input type="checkbox"/>	307	100020501	11/30/2011	11/30/2011	11	2011/11	SA	ROYALTY	102190	GEN	BET AND SEN ROYALTY 307 TO 190 AUG-11	91,315.03-	USD
<input type="checkbox"/>	307	100013491	09/30/2009	09/30/2009	9	2009/09	SA	SEPT09 ADJ III	102190	GEN	BET AND SEN ROYALTY 307 TO 190	86,915.54-	USD
<input type="checkbox"/>	307	100013199	08/31/2009	09/02/2009	8	2009/08	SA	AUG09 ADJ I	102190	GEN	BET AND SEN ROYALTY 307 TO 190	73,348.52-	USD
<input type="checkbox"/>	307	100029035	11/30/2014	12/05/2014	11	2014/11	SA	JAS 1114 109	102190	GEN	Correct Error in Sept BET Royalty	3,180.45-	USD
<input type="checkbox"/>	307	100036919	03/31/2019	04/02/2019	3	2019/03	SA	LMT 001	102190	GEN	BET & SEN ROYALTY 307 TO 190 2018 True Up	1,015.15-	USD
<input type="checkbox"/>	*											22,829,862.63-	USD

<sup>1</sup>Screenshot does not include all entries – abbreviated version shown.

## Exhibit 1L: Intercompany transfers between Purdue and Pharmaceutical Research Associates, Inc. for licensing the trademarks of Betadine and Senokot

According to Purdue Products L.P.'s (SAP company code 307) accounting records in SAP, charges for royalties to Purdue Products L.P. by PRA Inc. were consolidated through G/L account 102190 (Intercompany account - PRA Inc.). Royalty charges for 2008 are illustrated below.

G/L Account		102190		PRA									
Company Code		307											
CoCd	DocumentNo	Pstng Date	Doc. Date	Period	Year/month	Type	Cost Ctr	Reference	Account	Profit Ctr	Text	Amount in local cur.	LCurr
<input type="checkbox"/>	307 100007204	29.02.2008	03.03.2008	2	2008/02	SA		BILLING	102190	GEN	"ROYALTY BETA,SEN & XPR 307 TO 190"	196.432,96-	USD
<input type="checkbox"/>	307 100009133	31.07.2008	06.08.2008	7	2008/07	SA		JULY08 ADJ V	102190	GEN	"ROYALTY BETA,SEN & XPR 307 TO 190"	285.175,54-	USD
<input type="checkbox"/>	307 100007732	31.03.2008	04.04.2008	3	2008/03	SA		ROYALTY	102190	GEN	"ROYALTY BETA,SEN & XPR 307 TO 190"	172.324,89-	USD
<input type="checkbox"/>	307 100008183	30.04.2008	06.05.2008	4	2008/04	SA		ROYALTY	102190	GEN	"ROYALTY BETA,SEN & XPR 307 TO 190"	226.428,32-	USD
<input type="checkbox"/>	307 100008488	31.05.2008	04.06.2008	5	2008/05	SA		ROYALTY	102190	GEN	"ROYALTY BETA,SEN & XPR 307 TO 190"	226.518,26-	USD
<input type="checkbox"/>	307 100008812	30.06.2008	07.07.2008	6	2008/06	SA		ROYALTY	102190	GEN	"ROYALTY BETA,SEN & XPR 307 TO 190"	164.142,10-	USD
<input type="checkbox"/>	307 100009410	31.08.2008	04.09.2008	8	2008/08	SA		ROYALTY	102190	GEN	"ROYALTY BETA,SEN & XPR 307 TO 190"	200.393,66-	USD
<input type="checkbox"/>	307 100009707	30.09.2008	02.10.2008	9	2008/09	SA		ROYALTY	102190	GEN	"ROYALTY BETA,SEN & XPR 307 TO 190"	167.366,06-	USD
<input type="checkbox"/>	307 100009991	31.10.2008	06.11.2008	10	2008/10	SA		ROYALTY	102190	GEN	"ROYALTY BETA,SEN & XPR 307 TO 190"	293.146,16-	USD
<input type="checkbox"/>	307 100010276	30.11.2008	04.12.2008	11	2008/11	SA		ROYALTY	102190	GEN	"ROYALTY BETA,SEN & XPR 307 TO 190"	191.226,03-	USD
<input type="checkbox"/>	307 100010647	31.12.2008	08.01.2009	12	2008/12	SA		ROYALTY	102190	GEN	"ROYALTY BETA,SEN & XPR 307 TO 190"	226.589,23-	USD
<input type="checkbox"/>	307 100007108	31.01.2008	01.02.2007	1	2008/01	SA		ROYALTY I	102190	GEN	"ROYALTY BETA,SEN & XPR 307 TO 190"	192.272,13-	USD
*												2.542.015,34-	USD

## Exhibit 1L: Intercompany transfers between Purdue and Pharmaceutical Research Associates, Inc. for licensing the trademarks of Betadine and Senokot

According to Purdue Products L.P.'s (SAP company code 307) accounting records in SAP, charges for royalties to Purdue Products L.P. by PRA Inc. were consolidated through G/L account 102190 (Intercompany Account - PRA Inc.). Royalty charges for 2019 are illustrated below.

G/L Account		102190		PRA									
Company Code		307											
CoCd	DocumentNo	Pstng Date	Doc. Date	Period	Year/month	Type	Cost Ctr	Reference	Account	Profit Ctr	Text	Amount in local cur.	LCurr
<input type="checkbox"/>	307	100036740	01/31/2019	02/13/2019	1	2019/01	SA	LMT 001	102190	GEN	BET & SEN ROYALTY 307 TO 190 2018 True Up	160,290.43-	USD
<input type="checkbox"/>	307	100036796	02/28/2019	03/06/2019	2	2019/02	SA	LMT 001	102190	GEN	BET & SEN ROYALTY 307 TO 190 2018 True Up	163,381.35-	USD
<input type="checkbox"/>	307	100036884	03/31/2019	04/02/2019	3	2019/03	SA	LMT 001	102190	GEN	BET & SEN ROYALTY 307 TO 190 2018 True Up	245,174.50-	USD
<input type="checkbox"/>	307	100036919	03/31/2019	04/02/2019	3	2019/03	SA	LMT 001	102190	GEN	BET & SEN ROYALTY 307 TO 190 2018 True Up	1,015.15-	USD
<input type="checkbox"/>	307	100036970	04/30/2019	05/02/2019	4	2019/04	SA	LMT 001	102190	GEN	BET & SEN ROYALTY 307 TO 190 2018 True Up	205,243.28-	USD
<input type="checkbox"/>	307	100037054	05/31/2019	06/04/2019	5	2019/05	SA	LMT 001	102190	GEN	BET & SEN ROYALTY 307 TO 190 2019 True Up	178,726.36-	USD
<input type="checkbox"/>	307	100037123	06/30/2019	07/01/2019	6	2019/06	SA	LMT 001	102190	GEN	BET & SEN ROYALTY 307 TO 190 2019 True Up	190,306.35-	USD
<input type="checkbox"/>	307	100037200	07/31/2019	08/02/2019	7	2019/07	SA	LMT 001	102190	GEN	BET & SEN ROYALTY 307 TO 190 2019 True Up	157,754.89-	USD
<input type="checkbox"/>	307	100037277	08/31/2019	09/04/2019	8	2019/08	SA	LMT 001	102190	GEN	BET & SEN ROYALTY 307 TO 190 2019 True Up	180,511.50-	USD
*												1,482,403.81-	USD

## Exhibit 1L: Intercompany transfers between Purdue and Pharmaceutical Research Associates, Inc. for licensing the trademarks of Betadine and Senokot

Since 2007, royalties owed to PRA Inc. for the use of the Betadine and Senokot trademarks accrued without payment. In August 2018, PPLP paid the cumulative royalties owed to PRA Inc. on behalf of Avrio Health (PPLP's subsidiary).

The September 2018 cash payment from PPLP to PRA Inc. is illustrated below.

Company	Account Number	Account Description	DR	CR
190	100010	Cash Concentration	\$ 34,253,275	
190	102208	Purdue Pharma L.P.		\$ (34,253,275)
208	102190	PRA	\$ 34,253,275	
208	100010	Cash Concentration		\$ (34,253,275)

190: PRA Inc.

208: Purdue Pharma L.P.

## Exhibit 1L: Intercompany transfers between Purdue and Pharmaceutical Research Associates, Inc. for licensing the trademarks of Betadine and Senokot

These entries appear in SAP as follows:

**G/L Account Balance Display**

Document currency | Document currency | Document currency | Business area | Bus

Account number 102208 Purdue Pharma L.P.  
Company code 190 PRA Inc.  
Business area  
Fiscal year 2018  
All documents in currency \* Display currency USD

Period	Debit	Credit	Balance	Cumulative balance
Balance Carry...				32,946,294.64
1	212,414.31	89.60	212,324.71	33,158,619.35
2	63,925.26		63,925.26	33,222,544.61
3				33,222,544.61
4		125,750.02	125,750.02-	33,096,794.59
5				33,096,794.59
6				33,096,794.59
7				33,096,794.59
8		150,589.55	150,589.55-	32,946,205.04
9	1,471,943.79	34,253,275.48	32,781,331.69-	164,873.35
10	156,622.98		156,622.98	321,496.33
11		156,622.98	156,622.98-	164,873.35
12	225,667.87	237,180.48	11,512.61-	153,360.74
13				153,360.74
14				153,360.74
15				153,360.74
16				153,360.74
Total	2,130,574.21	34,923,508.11	32,792,933.90-	153,360.74

**G/L account document**

Overall No. 0100000926190 18 Doc. Currency USD

CoCd	DocumentNo	Year	Type	Doc. Date	Pstng Date	Reference	Crcy
Itm	PK Account	Account short text	Assignment				Amount Text
190	100000926	2018	SA	10/01/2018	09/30/2018	CWS	USD
1 40	100010	Cash Concentration	20181001				34,253,275.48 SENOKOT & BETADINE R
2 50	102208	Purdue Pharma L.P.	20181001				34,253,275.48-
208	100176647	2018	SA	10/01/2018	09/30/2018	CWS	USD
1 50	100010	Cash Concentration	20181001				34,253,275.48- SENOKOT & BETADINE R
2 40	102190	PRA	20181001				34,253,275.48



## Exhibit 1L: Intercompany transfers between Purdue and Pharmaceutical Research Associates, Inc. for licensing the trademarks of Betadine and Senokot

Per an internal analysis and verified in SAP, the \$34.3 million cash payment was composed of accrued royalties, excess cash from intercompany funding, and other items as described below.

Payment Type (\$M)	Amount
Accrued Royalties	\$ 23.3
Excess Cash Paid to PPLP	6.5
Intercompany Interest	2.2
██████████ Royalties	2.4
Other	(0.1)
<b>Total</b>	<b>\$ 34.3</b>

Per an internal analysis and verified in SAP, \$23.3 million in royalties were accrued from January 1, 2007 to August 31, 2018.

Per discussions with Purdue and TXP, from 2007 through 2017, PRA Inc. was part of the "PPLP bank group." PPLP was considered the banker of the group. Accordingly, all entities within the PPLP bank group would maintain a small cash balance. Any funds received by the entities would be sent to PPLP. Entities that needed cash for tax payments, life insurance or other benefit payments, etc. would receive the cash from PPLP. From 2007 through 2017, PRA Inc. sent PPLP \$10.6 million in cash and received \$4.1 million resulting in a net receivable due from PPLP of \$6.5 million.

In 1999, an agreement between The Purdue Frederick Company ("PF") and ██████████ was signed, whereby ██████████ would pay a ██████████ royalty on sales of Betadine Ophthalmic product. These rights were later assigned to PRA Inc. (the parent company of PF) who collected the cash from ██████████. Because this cash was transferred to PPLP (as described above), this created a payable from PPLP to PRA Inc.

Per discussions with Purdue and TXP, items included in the "Other" category are listed as miscellaneous activity.

## Exhibit 1L: Intercompany transfers between Purdue and Pharmaceutical Research Associates, Inc. for licensing the trademarks of Betadine and Senokot

Based on a preliminary analysis of the intercompany accounts (102190 – PRA Inc. and 102208 - Purdue Pharma L.P.) on Avrio Health's books (SAP company code 307), it appears the majority of the of the activity in 102190-307 relates to Betadine and Senokot royalties with the entirety or the majority of the balance in 102190-307 being transferred to 102208-307 each year via entries commonly labeled LCD (for "Lowest Common Denominator"). However, there is substantially greater activity in 102208-307 that is not related to Betadine and Senokot royalties.

Account 102190-307	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	Totals
Prior Year Cumulative Balance	\$ -	\$ -	\$ -	\$ -	\$ (793,634)	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	
Debits	2,579,111	1,778,836	2,118,103	2,406,423	2,497,491	3,093,669	1,941,797	1,836,673	1,842,634	1,799,753	2,282,816	2,867,360	27,044,666
Credits	(2,579,111)	(1,778,836)	(2,118,103)	(3,200,057)	(1,703,856)	(3,093,669)	(1,941,797)	(1,836,673)	(1,842,634)	(1,799,753)	(2,282,816)	(2,874,563)	(27,051,869)
Ending Cumulative Balance	\$ -	\$ -	\$ -	\$ -	\$ (793,634)	\$ -	\$ -	\$ -	\$ -	\$ -	\$ -	\$ (7,204)	
LCD Entries to 102208	\$ 2,572,236	\$ 1,778,836	\$ 2,118,103	\$ 2,406,423	\$ 2,497,491	\$ 3,093,485	\$ 1,941,797	\$ 1,836,673	\$ 1,842,326	\$ 1,783,214	\$ 150,590	\$ -	\$ 22,021,173
Other Non-102208 Transfer Debits	6,875	-	-	-	-	184	-	-	308	16,539	2,132,226	2,867,360	5,023,492
Total Debits	\$ 2,579,111	\$ 1,778,836	\$ 2,118,103	\$ 2,406,423	\$ 2,497,491	\$ 3,093,669	\$ 1,941,797	\$ 1,836,673	\$ 1,842,634	\$ 1,799,753	\$ 2,282,816	\$ 2,867,360	\$ 27,044,666
LCD Entries from 102208	\$ -	\$ -	\$ -	\$ (1,202,649)	\$ -	\$ (1,055,991)	\$ (154,920)	\$ -	\$ -	\$ -	\$ -	\$ -	\$ (2,413,560)
Royalty Charges	(2,542,015)	(1,771,497)	(2,112,558)	(1,992,739)	(1,700,138)	(2,036,722)	(1,785,568)	(1,833,050)	(1,838,701)	(1,766,378)	(1,968,093)	(1,482,404)	(22,829,863)
Other Non-Royalty or LCD Credits	(37,096)	(7,339)	(5,545)	(4,669)	(3,719)	(956)	(1,309)	(3,623)	(3,932)	(33,376)	(314,723)	(1,392,159)	(1,808,447)
Total Credits	\$ (2,579,111)	\$ (1,778,836)	\$ (2,118,103)	\$ (3,200,057)	\$ (1,703,856)	\$ (3,093,669)	\$ (1,941,797)	\$ (1,836,673)	\$ (1,842,634)	\$ (1,799,753)	\$ (2,282,816)	\$ (2,874,563)	\$ (27,051,869)
Account 102208-307	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	Totals
Prior Year Cumulative Balance	\$ 1,746,143	\$ 18,687,138	\$ 16,674,494	\$ 23,861,096	\$ 50,618,477	\$ 40,656,289	\$ 62,904,259	\$ 89,579,199	\$ 113,365,620	\$ 133,602,603	\$ 166,785,884	\$ (0)	
Debits	81,424,260	83,502,270	73,144,419	119,614,681	166,786,371	329,480,485	341,783,455	325,413,596	366,744,336	333,771,623	627,735,698	132,073,312	2,981,474,506
Credits	(64,483,265)	(85,514,914)	(65,957,817)	(92,857,300)	(176,748,559)	(307,232,515)	(315,108,515)	(301,627,175)	(346,507,353)	(300,588,342)	(794,521,582)	(132,073,312)	(2,983,220,649)
Ending Cumulative Balance	\$ 18,687,138	\$ 16,674,494	\$ 23,861,096	\$ 50,618,477	\$ 40,656,289	\$ 62,904,259	\$ 89,579,199	\$ 113,365,620	\$ 133,602,603	\$ 166,785,884	\$ (0)	\$ (0)	
LCD Entries to 102190	\$ -	\$ -	\$ -	\$ (1,202,649)	\$ -	\$ (1,055,991)	\$ (154,920)	\$ -	\$ -	\$ -	\$ -	\$ -	\$ (2,413,560)
Other Non-102190 Transfer Credits	81,424,260	83,502,270	73,144,419	120,817,330	166,786,371	330,536,476	341,938,375	325,413,596	366,744,336	333,771,623	627,735,698	132,073,312	2,983,888,066
Total Debits	\$ 81,424,260	\$ 83,502,270	\$ 73,144,419	\$ 119,614,681	\$ 166,786,371	\$ 329,480,485	\$ 341,783,455	\$ 325,413,596	\$ 366,744,336	\$ 333,771,623	\$ 627,735,698	\$ 132,073,312	\$ 2,981,474,506
LCD Entries from 102190	\$ 2,572,236	\$ 1,778,836	\$ 2,118,103	\$ 2,406,423	\$ 2,497,491	\$ 3,093,485	\$ 1,941,797	\$ 1,836,673	\$ 1,842,326	\$ 1,783,214	\$ 150,590	\$ -	\$ 22,021,173
Other Non-102190 Transfer Credits	(67,055,501)	(87,293,750)	(68,075,920)	(95,263,723)	(179,246,050)	(310,326,000)	(317,050,312)	(303,463,848)	(348,349,679)	(302,371,556)	(794,672,171)	(132,073,312)	(3,005,241,822)
Total Credits	\$ (64,483,265)	\$ (85,514,914)	\$ (65,957,817)	\$ (92,857,300)	\$ (176,748,559)	\$ (307,232,515)	\$ (315,108,515)	\$ (301,627,175)	\$ (346,507,353)	\$ (300,588,342)	\$ (794,521,582)	\$ (132,073,312)	\$ (2,983,220,649)

## **Exhibit 1M: Intercompany transfers between Purdue and Purdue Pharma (Canada) for manufacturing and packaging services**

Effective September 1, 2009, Purdue entered into a supply agreement with Purdue Pharma (Canada) for manufacturing and packaging services.

**THIS SUPPLY AGREEMENT**, is effective as of September 1, 2009 (the "**Effective Date**"), is by and between Purdue Pharma (Canada) ("Supplier") with a place of business at 575 Granite Court, Pickering, Ontario, Canada L1W 3W8 and Purdue Products L.P. ("PPLP"), with a place of business at One Stamford Forum, Stamford, CT 06901-3431.

### **RECITALS:**

**WHEREAS**, Supplier manufactures and packages pharmaceutical products, including the Products (as hereinafter defined in Section 1.20); and

**WHEREAS**, PPLP markets and distributes prescription and non-prescription medicines, including finished dosage non-prescription medicines; and

**WHEREAS**, PPLP has requested that Supplier manufacture, package and sell the Products to PPLP.

**WHEREAS**, subject to the terms and conditions set forth herein, PPLP wishes to distribute the Products and Supplier is agreeable to manufacturing, packaging and supplying the Products for distribution by PPLP as provided herein.

## Exhibit 1M: Intercompany transfers between Purdue and Purdue Pharma (Canada) for manufacturing and packaging services

According to the supply agreement, Purdue agreed to pay the prices below subject to annual adjustments.

### US Senokot (Calcium Sennosides) 2010 Prices

Note: All prices are in Canadian dollars

		<u>Cdn\$</u>
SNKT04	Senokot Sample 4s	
SNKT20	Senokot 20s	
SNKT50	Senokot 50s	
SNKT1W	Senokot 100s	
SNKT11	Senokot 100s HUD Blister	
SENS04	Senokot S Sample 4s	
SENS10	Senokot S 10s Blister	
SENS30	Senokot S 30s	
SENS60	Senokot S 60s	
SENS11	Senokot S 100s HUD Blister	

Senokot-S Tablets 10's Bonus Pack (10 + 4 tablets free)  
Senokot Tablets 20's Bonus Pack (20 + 4 tablets free)

## **Exhibit 1M: Intercompany transfers between Purdue and Purdue Pharma (Canada) for manufacturing and packaging services**

From September 1, 2009 to September 15, 2019, Purdue paid \$41.1 million to Purdue Pharma (Canada) pursuant to the supply agreement.

<b>Year</b>	<b>Payments</b>
2009	\$ 1,794,542
2010	2,466,513
2011	2,307,198
2012	5,409,689
2013	5,243,004
2014	4,518,539
2015	3,727,388
2016	3,271,075
2017	4,037,991
2018	4,293,057
2019	4,023,588
<b>Total</b>	<b>\$ 41,092,586</b>



## Exhibit 1M: Intercompany transfers between Purdue and Purdue Pharma (Canada) for manufacturing and packaging services

The table below presents Purdue's 2009 and 2019 payments to Purdue Pharma (Canada) as an example.

Company Code	Document Number	Document Type	Clearing Date	Clearing Document	Amount
409	1500000103	KZ	11/17/2009	1500000103	\$ 143,899
409	1500000104	KZ	11/18/2009	1500000104	1,184,025
409	1500000107	KZ	12/11/2009	1500000107	260,912
409	1500000108	KZ	12/31/2009	1500000108	205,706
<b>Total</b>					<b>\$ 1,794,542</b>

307	2000008871	ZP	1/11/2019	2000008883	\$ 100,764
307	2000008883	ZP	1/11/2019	2000008883	(100,764)
307	2000008895	ZP	1/16/2019	2000008895	100,764
307	2000008964	ZP	2/6/2019	2000008964	394,369
307	2000009015	ZP	2/27/2019	2000009015	177,053
307	2000009112	ZP	3/29/2019	2000009112	268,485
307	2000009119	ZP	4/3/2019	2000009119	383,452
307	2000009198	ZP	4/26/2019	2000009198	67,614
307	2000009211	ZP	5/1/2019	2000009211	231,943
307	2000009240	ZP	5/8/2019	2000009240	304,587
307	2000009288	ZP	5/22/2019	2000009288	304,235
307	2000009318	ZP	5/29/2019	2000009318	81,075
307	2000009349	ZP	6/5/2019	2000009349	68,898
307	2000009407	ZP	6/19/2019	2000009407	288,087
307	2000009456	ZP	7/3/2019	2000009456	461,587
307	2000009538	ZP	7/31/2019	2000009538	26,821
307	2000009590	ZP	8/14/2019	2000009590	141,870
307	2000009647	ZP	8/28/2019	2000009647	217,007
307	2000009691	ZP	9/4/2019	2000009691	89,060
307	2000009747	ZP	9/13/2019	2000009747	416,682
<b>Total</b>					<b>\$ 4,023,588</b>

## Exhibit 1M: Intercompany transfers between Purdue and Purdue Pharma (Canada) for manufacturing and packaging services

The SAP screenshots below illustrate that Purdue made cash payments to Purdue Pharma (Canada) for 2009 activity pursuant to the supply agreement.

Vendor 1022943  
Company Code 409  
  
Name PURDUE PHARMA CANADA  
City PICKERING

Account	CoCd	Reference	DocumentNo	Assignment	Type	Doc. Date	Postng Date	Net due dt	Blinc Date	FBk	PmtMthSu	Amount in local cur.	Amount in doc. curr.	Curr.	Clng doc.	Clearing	Text
<input type="checkbox"/> 1022943	409	WIRE TRANSFER	1500000104	WIRE TRANSFER	KZ	11/17/2009	11/18/2009	11/17/2009	11/17/2009			1,184,024.62	1,184,024.62	USD	1500000104	11/18/2009	
<input type="checkbox"/> 1022943	409	WIRE TRANSFER	1500000107	WIRE TRANSFER	KZ	12/10/2009	12/11/2009	12/10/2009	12/10/2009			260,912.48	260,912.48	USD	1500000107	12/11/2009	
<input type="checkbox"/> 1022943	409	WIRE TRANSFER	1500000108	WIRE TRANSFER	KZ	12/24/2009	12/31/2009	12/24/2009	12/24/2009			205,705.59	205,705.59	USD	1500000108	12/31/2009	
<input type="checkbox"/> 1022943	409	WIRE TRANSFER	1500000103	WIRE TRANSFER	KZ	11/16/2009	11/17/2009	11/16/2009	11/16/2009			143,899.26	143,899.26	USD	1500000103	11/17/2009	
												1,794,541.95	1,794,541.95	USD			

Doc.Type : KZ ( Vendor payment ) Normal document  
Doc. Number 1500000104 Company Code 409 Fiscal Year 2009  
Doc. Date 11/17/2009 Posting Date 11/18/2009 Period 11  
Calculate Tax ☐  
Ref.Doc. WIRE TRANSFER  
Doc. Currency USD

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	50	100010	Cash Concentration		GEN			1,185,005.78-	
2	40	700520	Realized FX	9001409	GEN			981.16	Foreign Exchange - Gain/Loss
3	25	1022943	PURDUE PHARMA CANADA		GEN			1,184,024.62	

## Exhibit 1M: Intercompany transfers between Purdue and Purdue Pharma (Canada) for manufacturing and packaging services

The SAP screenshots below illustrate that Purdue made cash payments to Purdue Pharma (Canada) for 2019 activity pursuant to the supply agreement.

Vendor 1022943  
Company Code 307  
  
Name PURDUE PHARMA CANADA  
City PICKERING

Account	CoCd	Reference	DocumentNo	Assignment	Type	Doc. Date	Postng Date	Net due dt	Blinc Date	PBk	FmtMthSu	Amount in local cur.	Amount in doc. curr.	Curr.	Clrng doc.	Clearing	Text
<input type="checkbox"/> 1022943	307		2000009456		ZP	07/03/2019	07/03/2019	07/03/2019	07/03/2019			461,586.72	461,586.72	USD	2000009456	07/03/2019	
<input type="checkbox"/> 1022943	307		2000009747		ZP	09/13/2019	09/13/2019	09/13/2019	09/13/2019			416,682.36	416,682.36	USD	2000009747	09/13/2019	
<input type="checkbox"/> 1022943	307		2000008964		ZP	02/06/2019	02/06/2019	02/06/2019	02/06/2019			394,368.96	394,368.96	USD	2000008964	02/06/2019	
<input type="checkbox"/> 1022943	307		2000009119		ZP	04/03/2019	04/03/2019	04/03/2019	04/03/2019			383,452.20	383,452.20	USD	2000009119	04/03/2019	
<input type="checkbox"/> 1022943	307		2000009240		ZP	05/08/2019	05/08/2019	05/08/2019	05/08/2019			304,586.76	304,586.76	USD	2000009240	05/08/2019	
<input type="checkbox"/> 1022943	307		2000009288		ZP	05/22/2019	05/22/2019	05/22/2019	05/22/2019			304,234.92	304,234.92	USD	2000009288	05/22/2019	
<input type="checkbox"/> 1022943	307		2000009407		ZP	06/19/2019	06/19/2019	06/19/2019	06/19/2019			288,087.00	288,087.00	USD	2000009407	06/19/2019	
<input type="checkbox"/> 1022943	307		2000009112		ZP	03/29/2019	03/29/2019	03/29/2019	03/29/2019			268,484.88	268,484.88	USD	2000009112	03/29/2019	
<input type="checkbox"/> 1022943	307		2000009211		ZP	05/01/2019	05/01/2019	05/01/2019	05/01/2019			231,942.84	231,942.84	USD	2000009211	05/01/2019	
<input type="checkbox"/> 1022943	307		2000009647		ZP	08/28/2019	08/28/2019	08/28/2019	08/28/2019			217,006.80	217,006.80	USD	2000009647	08/28/2019	
<input type="checkbox"/> 1022943	307		2000009015		ZP	02/27/2019	02/27/2019	02/27/2019	02/27/2019			177,053.16	177,053.16	USD	2000009015	02/27/2019	
<input type="checkbox"/> 1022943	307		2000009590		ZP	08/14/2019	08/14/2019	08/14/2019	08/14/2019			141,869.88	141,869.88	USD	2000009590	08/14/2019	
<input type="checkbox"/> 1022943	307		2000008895		ZP	01/16/2019	01/16/2019	01/16/2019	01/16/2019			100,763.53	100,763.53	USD	2000008895	01/16/2019	
<input type="checkbox"/> 1022943	307		2000008871		ZP	01/11/2019	01/11/2019	01/11/2019	01/11/2019			100,763.53	100,763.53	USD	2000008871	01/11/2019	
<input type="checkbox"/> 1022943	307		2000009691		ZP	09/04/2019	09/04/2019	09/04/2019	09/04/2019			89,059.68	89,059.68	USD	2000009691	09/04/2019	
<input type="checkbox"/> 1022943	307		2000009318		ZP	05/29/2019	05/29/2019	05/29/2019	05/29/2019			81,075.36	81,075.36	USD	2000009318	05/29/2019	
<input type="checkbox"/> 1022943	307		2000009349		ZP	06/05/2019	06/05/2019	06/05/2019	06/05/2019			68,897.52	68,897.52	USD	2000009349	06/05/2019	
<input type="checkbox"/> 1022943	307		2000009198		ZP	04/26/2019	04/26/2019	04/26/2019	04/26/2019			67,614.00	67,614.00	USD	2000009198	04/26/2019	
<input type="checkbox"/> 1022943	307		2000009538		ZP	07/31/2019	07/31/2019	07/31/2019	07/31/2019			26,821.41	26,821.41	USD	2000009538	07/31/2019	
<input type="checkbox"/> 1022943	307		2000008883		ZP	01/11/2019	01/11/2019	01/11/2019	01/11/2019			100,763.53	100,763.53	USD	2000008883	01/11/2019	
												4,023,587.98	4,023,587.98	USD			

Doc.Type : ZP ( Payment posting ) Normal document  
 Doc. Number 2000009456 Company Code 307 Fiscal Year 2019  
 Doc. Date 07/03/2019 Posting Date 07/03/2019 Period 07  
 Calculate Tax ☐  
 Doc. Currency USD  
 Payment Run ID 07/03/2019 - PAY9

Itm	PK	Account	Account short text	Cost Ctr	Profit Ctr	Order	Tx	Amount	Text
1	25	1022943	PURDUE PHARMA CANADA		GEN			461,586.72	
2	50	100010	Cash Concentration		GEN			461,586.72-	